

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/86, A61K 48/00	A1	(11) International Publication Number: WO 98/22609
		(43) International Publication Date: 28 May 1998 (28.05.98)

(21) International Application Number: PCT/US97/21494

(22) International Filing Date: 20 November 1997 (20.11.97)

(30) Priority Data:
08/752,760 20 November 1996 (20.11.96) US

(71) Applicant (for all designated States except US): GENZYME CORPORATION [US/US]; One Mountain Road, Framingham, MA 01701 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ARMENTANO, Donna, E. [US/US]; 352 Brighthon Street, Belmont, MA 02178 (US). GREGORY, Richard, J. [US/US]; 2 Wintergreen Lane, Westford, MA 01866 (US). SMITH, Alan, E. [GB/US]; 1 Mill Street, Dover, MA 02030 (US).

(74) Agent: SEIDE, Rochelle, K.; Baker & Botts, LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: CHIMERIC ADENOVIRAL VECTORS

(57) Abstract

A chimeric adenoviral vector is provided that comprises nucleotide sequence of a first adenovirus, wherein all or part of at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by all or part of the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell. Compositions comprising such vectors and methods of using such vectors to deliver transgenes to target mammalian cells, particularly airway epithelial cells, are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

Description

Chimeric Adenoviral Vectors

5 Introduction

The present invention relates to chimeric adenoviral vectors, that is, vectors comprising DNA from more than one serotype of adenovirus, which offer enhanced infection efficiency of target cells in order to deliver one or more therapeutically useful nucleotide sequences, including transgenes, therein. Such a nucleotide
10 sequence may comprise a gene not otherwise present in the target cell that codes for a therapeutic and/or biologically active protein, or may represent, for example, an active copy of a gene that is already present in the target cell, but in a defective or deficient form.

15 Background of the Invention

One of the fundamental challenges now facing medical practitioners is that although the defective genes that are associated with numerous inherited diseases (or that represent disease risk factors including for various cancers) have been isolated and characterized, methods to correct the disease states themselves by providing
20 patients with normal copies of such genes (the technique of gene therapy) are substantially lacking. Accordingly, the development of improved methods of intracellular delivery therefor is of great medical importance. Examples of diseases that it is hoped can be treated by gene therapy include inherited disorders such as cystic fibrosis, Gaucher's disease, Fabry's disease, and muscular dystrophy.

25 Representative of acquired disorders that can be treated are: (1) for cancers: multiple myeloma, leukemias, melanomas, ovarian carcinoma and small cell lung cancer; (2) for cardiovascular conditions: progressive heart failure, restenosis, and hemophilias; and (3) for neurological conditions: traumatic brain injury.

- 2 -

Gene therapy requires successful transfer of nucleic acid to the target cells of a patient. Gene transfer may generally be defined as the process of introducing an expressible polynucleotide (for example a gene, a cDNA, or an mRNA patterned thereon) into a cell. In a particular application of this approach, successful expression
5 of an encoding polynucleotide leads to production in the cells of a normal protein and leads to correction of a disease state associated with an abnormal gene. Therapies based on providing such proteins directly to target cells (protein replacement therapy) have generally proved ineffective since, for example, the cell membrane presents a selectively permeable barrier to entry. Thus there is great interest in alternative
10 methods to cause delivery of therapeutic proteins, especially by transfer of the relevant polynucleotide, often referred to as a transgene.

Viral vectors have been used with increasing frequency to date to deliver transgenes to target cells. Most attempts to use viral vectors for gene therapy have relied on retrovirus-based vectors, chiefly because of their ability to integrate into the
15 cellular genome. However, the disadvantages of retroviral vectors are becoming increasingly clear, including their tropism for dividing cells only, the possibility of insertional mutagenesis upon integration into the cell genome, decreased expression of the transgene over time, rapid inactivation by serum complement, and the possibility of generation of replication-competent retroviruses. See, for example, D. Jolly, et al.,
20 Cancer Gene Therapy, 1, 1994, pp. 51-64, and C.P. Hodgson, et al., Bio Technology, 13, 1995, pp. 222-225. Such disadvantages have led to the development of other viral-based vector systems, including those derived from adenoviruses.

Adenovirus (Ad) is a nuclear DNA virus with a genome of about 36 kb, which has been well-characterized through studies in classical genetics and molecular
25 biology. A detailed discussion of adenovirus is found in Thomas Shenk, "Adenoviridae and their Replication", and M. S. Horwitz, "Adenoviruses", Chapters 67 and 68, respectively, in Virology, B.N. Fields et al., eds., 2nd edition, Raven Press, Ltd., New York, 1996, and reference therein is found to numerous aspects of adenovirus pathology, epidemiology, structure, replication, genetics and classification.

- 3 -

In a simplified form, the adenoviral genome is classified into early (known as E1-E4) and late (known as L1-L5) transcriptional units, referring to the generation of two temporal classes of viral proteins. The demarcation between these events is viral DNA replication.

5 The human adenoviruses are divided into numerous serotypes (approximately 47, numbered accordingly and classified into 6 subgroups: A, B, C, D, E and F), based upon properties including hemagglutination of red blood cells, oncogenicity, DNA base and protein amino acid compositions and homologies, and antigenic relationships. Additional background information concerning Ad serotype
10 classification, including that for subgroup D, can be found, for example, in F. Deryckere et al., *Journal of Virology*, 70, 1996, pp. 2832-2841; and A. Bailey et al., *Virology*, 205, 1994, pp. 438-452, and in other art-recognized references.

Adenoviruses are nonenveloped, regular icosahedrons (having 20 triangular surfaces and 12 vertices) that are about 65-80 nm in diameter. A protein called fiber
15 projects from each of these vertices. The fiber protein is itself generally composed of 3 identical polypeptide chains, although the length thereof varies between serotypes. The protein coat (capsid) is composed of 252 subunits (capsomeres), of which 240 are hexons, and 12 are pentons. Each penton comprises a penton base, on the surface of the capsid, and a fiber protein projecting from the base. The Ad 2 penton base protein,
20 for example, has been determined to be a 8 x 9 nm ring shaped complex composed of 5 identical protein subunits of 571 amino acids each.

Current understanding of adenovirus-cell interactions suggests that adenovirus utilizes two cellular receptors to attach to, and then infect a target cell. It has been further suggested that the fiber protein of an infecting adenovirus first attaches to a
25 receptor, the identity of which is still unknown, and then penton base attaches to a further receptor, often a protein of the alpha integrin family. It has been determined that alpha-integrins often recognize short amino acid sequences on other cellular proteins for attachment purposes including the tripeptide sequence Arg-Gly-Asp (abbreviated RGD). An RGD sequence is also found in the penton base protein of

- 4 -

adenovirus and is currently understood in the art to mediate attachment of Ad to alpha integrins.

Recombinant adenoviruses have several advantages for use as gene transfer vectors, including tropism for both dividing and non-dividing cells, minimal
5 pathogenic potential, ability to replicate to high titer for preparation of vector stocks, and the potential to carry large inserts (Berkner, K.L., *Curr. Top. Micro. Immunol.* 158:39-66, 1992; Jolly, D., *Cancer Gene Therapy* 1:51-64, 1994).

The carrying capacity of an adenovirus vector is proportional to the size of the adenovirus genome present in the vector. For example, a capacity of about 8 kb can
10 be created from the deletion of certain regions of the virus genome dispensable for virus growth, e.g., E3, and the deletion of a genomic region such as E1 whose function may be restored in trans from 293 cells (Graham, F.L., *J. Gen. Virol.* 36:59-72, 1977) or A549 cells (Imler et al., *Gene Therapy* 3:75-84, 1996). Such E1-deleted vectors are rendered replication-defective, which is desirable for the engineering of adenoviruses
15 for gene transfer. The upper limit of vector DNA capacity for optimal carrying capacity is about 105%-108% of the length of the wild-type genome. Further adenovirus genomic modifications are possible in vector design using cell lines which supply other viral gene products in trans, e.g., complementation of E2a (Zhou et al., *J. Virol.* 70:7030-7038, 1996), complementation of E4 (Krougliak et al., *Hum. Gene*
20 *Ther.* 6:1575-1586, 1995; Wang et al., *Gene Ther.* 2:775-783, 1995), or complementation of protein IX (Caravokyri et al., *J. Virol.* 69:6627-6633, 1995; Krougliak et al., *Hum. Gene Ther.* 6:1575-1586, 1995). Maximal carrying capacity can be achieved using adenoviral vectors deleted for all viral coding sequences (Kochanek et al., *Proc. Natl. Acad. Sci. USA* 93:5731-5736, 1996; Fisher et al.,
25 *Virology* 217:11-22, 1996).

Transgenes that have been expressed to date by adenoviral vectors include p53 (Wills et al., *Human Gene Therapy* 5:1079-188, 1994); dystrophin (Vincent et al., *Nature Genetics* 5:130-134, 1993; erythropoietin (Descamps et al., *Human Gene Therapy* 5:979-985, 1994; ornithine transcarbamylase (Stratford-Perricaudet et al.,

- 5 -

Human Gene Therapy 1:241-256, 1990; We et al., J. Biol. Chem. 271:3639-3646, 1996;); adenosine deaminase (Mitani et al., Human Gene Therapy 5:941-948, 1994); interleukin-2 (Haddada et al., Human Gene Therapy 4:703-711, 1993); and α 1-antitrypsin (Jaffe et al., Nature Genetics 1:372-378, 1992); thrombopoietin
5 (Ohwada et al., Blood 88:778-784, 1996); and cytosine deaminase (Ohwada et al., Hum. Gene Ther. 7:1567-1576, 1996).

The particular tropism of adenoviruses for cells of the respiratory tract has particular relevance to the use of adenovirus in gene therapy for cystic fibrosis (CF), which is the most common autosomal recessive disease in Caucasians. The disease is
10 caused by the presence of one or more mutations in the gene that encodes a protein known as cystic fibrosis transmembrane conductance regulator (CFTR), and which regulates the movement of ions (and therefore fluid) across the cell membrane of epithelial cells, including lung epithelial cells. Abnormal ion transport in airway cells leads to abnormal mucous secretion, inflammation and infection, tissue damage,
15 and eventually death. Mutations in the CFTR gene that disturb the cAMP-regulated Cl⁻ channel in airway epithelia result in pulmonary dysfunction (Zabner et al., Nature Genetics 6:75-83, 1994). Adenovirus vectors engineered to carry the CFTR gene have been developed (Rich et al., Human Gene Therapy 4:461-476, 1993) and studies have shown the ability of these vectors to deliver CFTR to nasal epithelia of CF patients
20 (Zabner et al., Cell 75:207-216, 1993), the airway epithelia of cotton rats and primates (Zabner et al., Nature Genetics 6:75-83, 1994), and the respiratory epithelium of CF patients (Crystal et al., Nature Genetics 8:42-51, 1994). Recent studies have shown that administering an adenoviral vector containing a DNA sequence encoding CFTR to airway epithelial cells of CF patients can restore a functioning chloride ion channel
25 in the treated epithelial cells (Zabner et al., J. Clin. Invest. 97:1504-1511, 1996; U.S. Patent No. 5,670,488 issued September 23, 1997).

Serotype classification is partly based on viral surface protein sequence variation. Because the infectious capabilities of the virus are associated with the surface protein interactions of the virus with cellular proteins, the serotype is an

- 6 -

important determinant of viral entry into target cells, and can account for the infectious heterogeneity of adenovirus serotypes. Most adenoviral vectors have been constructed using adenovirus serotypes from the well-studied group C adenoviruses, especially Ad 2 and Ad 5. However, other adenovirus serotypes display infectious
5 properties that are relevant to the further design of improved adenoviral vectors, for example, those derived from subgroup D, which display enhanced tropism for human airway epithelial cells.

It is widely hoped that gene therapy will provide a long lasting and predictable form of therapy for certain disease states, and it is likely the only form of therapy
10 suitable for many inherited diseases. Although adenoviral vectors are currently in clinical use and have shown therapeutic promise, a need remains to improve the infection efficiency of these vectors in order to further improve their gene transfer capabilities. The present invention addresses this goal.

15 Summary Of The Invention

The present invention provides for chimeric adenoviral vectors which offer enhanced infection efficiency of target cells for the delivery of one or more transgenes. In a representative aspect of the invention, the vectors comprise nucleotide sequences coding for therapeutically useful proteins and have enhanced tropism for airway
20 epithelial cells.

Accordingly, there are provided chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the
25 corresponding gene from a second adenovirus belonging to subgroup D. These vectors may further comprising a transgene operably linked to a eucaryotic promoter or other regulatory elements to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for Ad fiber, hexon or penton base.

- 7 -

In a further preferred embodiment of the invention, there are provided chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a
5 portion of the corresponding gene from a second adenovirus belonging to subgroup D. These vectors may further comprising a transgene operably linked to a eucaryotic promoter or other regulatory elements to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for a portion of Ad fiber, hexon or penton base.

10 Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide selected from the group consisting of Ad fiber, a fragment of Ad fiber, Ad hexon, a fragment of Ad hexon, Ad penton base, and a fragment of Ad penton base. In a preferred embodiment, said second adenovirus is selected from the group consisting of serotypes Ad 9, Ad 15, Ad
15 17, Ad 19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39. In preferred embodiments of the chimeric adenoviral vectors, the first adenovirus is selected from the group consisting of Ad 2, Ad 5, and Ad 12.

The invention is also directed to compositions comprising the chimeric adenoviral vectors of the invention. Additional aspects of the invention include
20 methods to use the chimeric adenoviral vectors of the invention to deliver transgenes to mammalian target cells, for example, to the airway epithelial cells of patients.

A still further representative aspect of the invention involves a method of providing a therapeutic and/or biologically active protein to the airway epithelial cells of a patient by administering to said cells an adenoviral vector comprising elements of
25 an Ad 17 genome, and a transgene encoding said therapeutic protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said therapeutic protein is expressed, and therapeutic benefit is produced in said airway epithelial cells.

- 8 -

These and other aspects of the present invention are described in the Detailed Description of the Invention which follows directly.

Brief Description of the Drawings

5 FIGURE 1 depicts infection of NHBE cells by Ad 2.

FIGURE 2 depicts infection of NHBE cells by Ad 17.

FIGURE 3 plots the result of binding to human nasal polyp epithelial cell isolates by Ad 2 and Ad 17.

FIGURE 4 is a map of the vector Ad2/ β gal-2/fiber Ad 17.

10 FIGURE 5 shows a comparison of the amino acid sequence of penton base from Ad 17 (top) [SEQ ID NO: 4] and Ad 2 (bottom) [SEQ ID NO: 5], and further depicts the variable RGD containing region.

FIGURE 6 depicts an amino acid sequence pileup for penton base from particular Ad serotypes, including f10 (from fowl) [SEQ ID NO: 6 through SEQ ID
15 NO: 10].

FIGURE 7 shows a comparison of the amino acid sequence of fiber from Ad 17 (top) [SEQ ID NO: 11] and Ad 2 (bottom) [SEQ ID NO: 12].

FIGURE 8 depicts an amino acid sequence pileup for fiber from particular Ad serotypes [SEQ ID NO: 11 through SEQ ID NO: 22], including two forms of serotype
20 40 (40-1 and 40-2) which differ in that one variant has two (but non-identical) copies of the fiber gene.

FIGURE 9 shows the infection efficiency of colon cancer cell lines by adenovirus serotypes.

FIGURE 10 shows the infection efficiency of cancer cell lines by adenovirus
25 serotypes.

Provided in the Sequence Listing attached hereto are also:

SEQ ID NO: 1, the complete nucleotide sequence of Ad 17;

SEQ ID NO: 2, the complete encoding nucleotide sequence for Ad 17 fiber;

- 9 -

SEQ ID NO: 3, the complete encoding nucleotide sequence for Ad 17 penton base.

Detailed Description of the Invention

5 The present invention provides for chimeric adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vectors
10 further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence correspond to the gene encoding the Ad fiber, hexon or penton base proteins, or combinations thereof.

 In a further preferred embodiment of the invention, there are provided chimeric
15 adenoviral vectors comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a portion of the corresponding gene from a second adenovirus belonging to subgroup D, said vectors further comprising a transgene operably linked to a eucaryotic promoter to
20 allow for expression therefrom in a mammalian cell. In a representative aspect thereof, the replaced encoding sequence codes for a portion of the Ad fiber, hexon or penton base proteins, or combinations thereof. Where a portion of a gene from a second adenovirus is used to construct a chimeric adenoviral vector, such sequence will have a length sufficient to confer a desired serotypic-specific virus-cell interaction to the
25 vector.

 The present invention involves the recognition that adenoviral vectors that are either based substantially upon the genome of Ad serotypes classified in subgroup D, or that contain certain Ad-protein encoding polynucleotide sequences of subgroup D adenovirus, are particularly effective at binding to, and internalizing within, human

- 10 -

cells, such that therapeutic transgenes included in the adenoviral vector are efficiently expressed. This discovery is particularly surprising given that adenovirus serotypes of subgroup D are not clinically associated with human respiratory disease, and that, for example association with conjunctivitis is more typical. The recognition of this

5 tropism is of particular relevance for the treatment by gene therapy of recognized disease states such as cystic fibrosis or α 1-antitrypsin deficiency. This discovery is particularly surprising given that adenovirus serotypes of subgroup D are not clinically associated with human respiratory disease, and that, for example association with conjunctivitis is more typical. The recognition of this tropism is of particular relevance

10 for the treatment by gene therapy of recognized disease states such as cystic fibrosis or α 1-antitrypsin deficiency.

In a representative aspect of the invention, the adenoviral vectors further comprise nucleotide sequences coding for one or more transgenes and have enhanced tropism for airway epithelial cells. Preferably, the chimeric adenoviral vectors are

15 replication-defective, a feature which contributes to the enhanced safety of adenoviral vectors administered to individuals.

Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide selected from the group consisting of Ad fiber, a fragment of Ad fiber, Ad hexon, a fragment of Ad hexon, Ad penton base, and

20 a fragment of Ad penton base. In a preferred embodiment, said second adenovirus is selected from the group consisting of serotypes Ad 9, Ad 15, Ad 17, Ad 19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39. In a most preferred embodiment, the second adenovirus is Ad 17. In other preferred embodiments of the chimeric adenoviral vectors, the first adenovirus is selected from the group consisting of Ad 2,

25 Ad 5, and Ad 12.

There is substantial evidence that any reported transforming properties of the E4 region of certain subgroup D serotypes do not extend to Ad serotypes whose use is preferred according to the practice of the present invention (see, for example, R. Javier

- 11 -

et al., Science, 257, 1992, pp. 1267-1271). It is expected also that, for example, individual ORFs of subgroup D E4 region, such as ORF1, could be deleted.

Additional aspects of the invention include methods to provide biologically active and/or therapeutic proteins to mammalian cells, including, but not limited to, the airway epithelial cells of individuals, in order to provide phenotypic benefit. According to this aspect of the invention, chimeric adenoviral vectors are used in which a nucleotide sequence of a first adenovirus is replaced by the corresponding nucleotide sequence of a second adenovirus. Preferably, the second adenovirus is a member of subgroup D, and the replaced nucleotide sequence encodes a polypeptide encoding all or part of Ad fiber, Ad hexon, or Ad penton base, or combinations thereof.

A still further representative aspect of the invention involves providing a biologically active and/or therapeutic protein in the airway epithelial cells of a patient by administering to said cells an adenoviral vector comprising elements of an Ad 17 genome, and a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said protein is expressed, and the desired phenotypic benefit is produced in said airway epithelial cells. According to the practice of the invention, it is preferred that an chimeric adenovirus vector utilized to deliver a transgene to the respiratory epithelium (including that of the nasal airway, trachea, and bronchi and alveoli of the lung), or to other tissues of the body, comprise serotypes within subgroup D, as such classification is recognized in the art.

In order to construct the chimeric adenoviral vectors of the invention, reference may be made to the substantial body of literature on how such vectors may be designed, constructed and propagated using techniques from molecular biology and microbiology that are well-known to the skilled artisan. Specific examples of adenoviral vector genomes which can be used as the backbone for a chimeric adenoviral vector of the invention include, for example, Ad2/CFTR-1 and Ad2/CFTR-2 and others described in U. S. Patent No. 5,670,488, issued September 23, 1997

- 12 -

(incorporated herein by reference). Such vectors may include deletion of the E1 region, partial or complete deletion of the E4 region, and deletions within, for example, the E2 and E3 regions. Within the scope of the invention are, for example, chimeric vectors which contain an Ad 2 backbone with one or more Ad 17 capsid proteins or fragments thereof in the virus. Other adenoviral vector genomic designs which can be used in the chimeric adenoviral vectors of the invention include those derived from allowed U.S. Patent Application Serial No. 08/409,874, filed March 24, 1995, and allowed U.S. Patent Application Serial No. 08/540,077, filed October 6, 1995 (both incorporated herein by reference).

To construct the recombinant chimeric adenoviral vectors of the invention which contain a transcription unit, the skilled artisan can use the standard techniques of molecular biology to engineer a transgene or a capsid protein into a backbone vector genome (Berkner, K.L., Curr. Top. Micro. Immunol. 158:39-66, 1992). For example, a plasmid containing a transgene and any operably linked regulatory elements inserted into an adenovirus genomic fragment can be co-transfected with a linearized viral genome derived from an adenoviral vector of interest into a recipient cell under conditions whereby homologous recombination occurs between the genomic fragment and the virus. Preferably, a transgene is engineered into the site of an E1 deletion. As a result, the transgene is inserted into the adenoviral genome at the site in which it was cloned into the plasmid, creating a recombinant adenoviral vector. The chimeric adenoviral vectors can also be constructed using standard ligation techniques, for example, removing a restriction fragment containing a fiber gene from a first adenovirus and ligating into that site a restriction fragment containing a fiber gene from a second adenovirus. A representative example of a chimeric adenoviral vector of the invention is Ad2/ β gal-2 fiber 17 (exemplified in Example 6).

Construction of the chimeric adenoviral vectors can be based on adenovirus DNA sequence information widely available in the field, e.g., nucleic acid sequence databases such as GenBank.

- 13 -

Preparation of replication-defective chimeric adenoviral vector stocks can be accomplished using cell lines that complement viral genes deleted from the vector, e.g., 293 or A549 cells containing the deleted adenovirus E1 genomic sequences. The use of HER3 cells (human embryonic retinoblasts transformed by Ad 12), as a
5 complementing cell line is of note. After amplification of plaques in suitable complementing cell lines, the viruses can be recovered by freeze-thawing and subsequently purified using cesium chloride centrifugation. Alternatively, virus purification can be performed using chromatographic techniques, e.g., as set forth in International Application No. PCT/US96/13872, filed August 30, 1996, incorporated
10 herein by reference.

Titers of replication-defective chimeric adenoviral vector stocks can be determined by plaque formation in a complementing cell line, e.g., 293 cells. End-point dilution using an antibody to the adenoviral hexon protein may be used to quantitate virus production or infection efficiency of target cells (Armentano et al.,
15 Hum. Gene Ther. 6:1343-1353, 1995, incorporated herein by reference).

Transgenes which can be delivered and expressed from a chimeric adenoviral vector of the invention include, but are not limited to, those encoding enzymes, blood derivatives, hormones, lymphokines such as the interleukins and interferons, coagulants, growth factors, neurotransmitters, tumor suppressors, apolipoproteins,
20 antigens, and antibodies, and other biologically active proteins. Specific transgenes which may be encoded by the chimeric adenoviral vectors of the invention include, but are not limited to, cystic fibrosis transmembrane regulator (CFTR), dystrophin, glucocerebrosidase, tumor necrosis factor, p53, p21, herpes simplex thymidine kinase and gancyclovir, retinoblastoma (Rb), and adenosine deaminase (ADA). Transgenes
25 encoding antisense molecules or ribozymes are also within the scope of the invention. The vectors may contain one or more transgenes under the control of one or more regulatory elements.

In addition to containing the DNA sequences encoding one or more transgenes, the chimeric adenoviral vectors of the invention may contain any

- 14 -

expression control sequences such as a promoter or enhancer, a polyadenylation element, and any other regulatory elements that may be used to modulate or increase expression, all of which are operably linked in order to allow expression of the transgene. The use of any expression control sequences, or regulatory elements,
5 which facilitate expression of the transgene is within the scope of the invention. Such sequences or elements may be capable of generating tissue-specific expression or be susceptible to induction by exogenous agents or stimuli.

Infection of target cell by the chimeric adenoviral vectors of the invention may also be facilitated by the use of cationic molecules, such as cationic lipids as disclosed
10 in PCT Publication No. WO96/18372, published June 20, 1996, incorporated herein by reference.

Cationic amphiphiles have a chemical structure which encompasses both polar and non-polar domains so that the molecule can simultaneously facilitate entry across a lipid membrane with its non-polar domain while its cationic polar domain attaches
15 to a biologically useful molecule to be transported across the membrane.

Cationic amphiphiles which may be used to form complexes with the chimeric adenoviral vectors of the invention include, but are not limited to, cationic lipids, such as DOTMA (Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417, 1987) (N-[1-(2,3-dioletoxy)propyl]-N,N,N - trimethylammonium chloride); DOGS
20 (dioctadecylamidoglycylspermine) (Behr et al., Proc. Natl. Acad. Sci. USA 86:6982-6986, 1989); DMR1E (1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide) (Felgner et al., J. Biol. Chem. 269:2550-2561, 1994; and DC-chol (3B [N-N', N'-dimethylaminoethane) -carbamoyl] cholesterol) (U.S. Patent No. 5, 283,185 to Epand et al.). The use of other cationic amphiphiles recognized in the art or which
25 come to be discovered is within the scope of the invention.

In preferred embodiments of the invention, the cationic amphiphiles useful to complex with and facilitate transfer of the vectors of the invention are those lipids which are described in PCT Publication No. WO96/18372, published June 20, 1996, which is incorporated herein by reference. Preferred cationic amphiphiles described

- 15 -

herein to be used in the delivery of the plasmids and/or viruses are GL-53, GL-67, GL-75, GL-87, GL-89, and GL-120, including protonated, partially protonated, and deprotonated forms thereof. Further embodiments include the use of non-T-shaped amphiphiles as described on pp. 22-23 of the aforementioned PCT application,
5 including protonated, partially protonated and deprotonated forms thereof. Most preferably, the cationic amphiphile which can be used to deliver the vectors of the invention is spermine cholesterol carbamate (GL-67).

In the formulation of compositions comprising the chimeric adenoviral vectors of the invention, one or more cationic amphiphiles may be formulated with neutral co-
10 lipids such as dileoylphosphatidylethanolamine (DOPE) to facilitate delivery of the vectors into a cell. Other co-lipids which may be used in these complexes include, but are not limited to, diphytanoylphosphatidylethanolamine, lyso-phosphatidylethanolamines, other phosphatidylethanolamines, phosphatidylcholines, lyso-phosphatidylcholines and cholesterol. A preferred molar ratio of cationic
15 amphiphile to colipid is 1:1. However, it is within the scope of the invention to vary this ratio, including also over a considerable range. In a preferred embodiment of the invention, the cationic amphiphile GL-67 and the neutral co-lipid DOPE are combined in a 1:2 molar ratio, respectively, before complexing with a chimeric adenoviral vector for delivery to a cell.

20 In the formulation of complexes containing a cationic amphiphile with a chimeric adenoviral vector, a preferred range of 10^7 - 10^{10} infectious units of virus may be combined with a range of 10^4 - 10^6 cationic amphiphile molecules/viral particle.

The infection efficiency of the chimeric adenoviral vectors of the invention
25 may be assayed by standard techniques to determine the infection of target cells. Such methods include, but are not limited to, plaque formation, end-point dilution using, for example, an antibody to the adenoviral hexon protein, and cell binding assays using radiolabelled virus. Improved infection efficiency may be characterized as an increase in infection of at least an order of magnitude with reference to a control virus. Where

- 16 -

a chimeric adenoviral vector encodes a marker or other transgene, relevant molecular assays to determine expression include the measurement of transgene mRNA, by, for example, Northern blot, S1 analysis or reverse transcription-polymerase chain reaction (RT-PCR). The presence of a protein encoded by a transgene may be detected by

5 Western blot, immunoprecipitation, immunocytochemistry, or other techniques known to those skilled in the art. Marker-specific assays can also be used, such as X-gal staining of cells infected with a chimeric adenoviral vector encoding β -galactosidase.

In order to determine transgene expression and infection efficiency in vivo using the constructs and compositions of the invention, animal models may be

10 particularly relevant in order to assess transgene persistence against a background of potential host immune response. Such a model may be chosen with reference to such parameters as ease of delivery, identity of transgene, relevant molecular assays, and assessment of clinical status. Where the transgene encodes a protein whose lack is associated with a particular disease state, an animal model which is representative of

15 the disease state may optimally be used in order to assess a specific phenotypic result and clinical improvement. However, it is also possible that particular chimeric adenoviral vectors of the invention display enhanced infection efficiency only in human model systems, e.g., using primary cell cultures, tissue explants, or permanent cell lines. In such circumstances where there is no animal model system available in

20 which to model the infection efficiency of a chimeric adenoviral vector with respect to human cells, reference to art-recognized human cell culture models will be most relevant and definitive.

Relevant animals in which the chimeric adenoviral vectors may be assayed include, but are not limited to, mice, rats, monkeys, and rabbits. Suitable mouse

25 strains in which the vectors may be tested include, but are not limited to, C3H, C57Bl/6 (wild-type and nude) and Balb/c (available from Taconic Farms, Germantown, New York).

Where it is desirable to assess the host immune response to vector administration, testing in immune-competent and immune-deficient animals may be

- 17 -

compared in order to define specific adverse responses generated by the immune system. The use of immune-deficient animals, e.g., nude mice, may be used to characterize vector performance and persistence of transgene expression, independent of an acquired host response.

5 In a particular embodiment where the transgene is the gene encoding cystic fibrosis transmembrane regulator protein (CFTR) which is administered to the respiratory epithelium of test animals, expression of CFTR may be assayed in the lungs of relevant animal models, for example, C57Bl/6 or Balb/c mice, cotton rats, or Rhesus monkeys. Molecular markers which may be used to determine expression
10 include the measurement of CFTR mRNA, by, for example, Northern blot, S1 analysis or RT-PCR. The presence of the CFTR protein may be detected by Western blot, immunoprecipitation, immunocytochemistry, or other techniques known to those skilled in the art. Such assays may also be used in tissue culture where cells deficient in a functional CFTR protein and into which the chimeric adenoviral vectors have
15 been introduced may be assessed to determine the presence of functional chloride ion channels - indicative of the presence of a functional CFTR molecule.

 The chimeric adenoviral vectors of the invention have a number of in vivo and in vitro utilities. The vectors can be used to transfer a normal copy of a transgene encoding a biologically active protein to target cells in order to remedy a deficient or
20 dysfunctional protein. The vectors can be used to transfer marked transgenes (e.g., containing nucleotide alterations) which allow for distinguishing expression levels of a transduced gene from the levels of an endogenous gene. The chimeric adenoviral vectors can also be used to define the mechanism of specific viral protein-cellular protein interactions that are mediated by specific virus surface protein sequences. The
25 vectors can also be used to optimize infection efficiency of specific target cells by adenoviral vectors, for example, using a chimeric adenoviral vector containing Ad 17 fiber protein to infect human nasal polyp cells. Where it is desirable to use an adenoviral vector for gene transfer to cancer cells in an individual, a chimeric adenoviral vector can be chosen which selectively infects the specific type of target

- 18 -

cancer cell and avoids promiscuous infection. Where primary cells are isolated from a tumor in an individual requiring gene transfer, the cells may be tested against a panel of chimeric adenoviral vectors to select a vector with optimal infection efficiency for gene delivery. The vectors can further be used to transfer tumor antigens to dendritic
5 cells which can then be delivered to an individual to elicit an anti-tumor immune response. Chimeric adenoviral vectors can also be used to evade undesirable immune responses to particular adenovirus serotypes which compromise the gene transfer capability of adenoviral vectors.

The present invention is further directed to compositions containing the
10 chimeric adenoviral vectors of the invention which can be administered in an amount effective to deliver one or more desired transgenes to the cells of an individual in need of such molecules and cause expression of a transgene encoding a biologically active protein to achieve a specific phenotypic result. The cationic amphiphile-plasmid complexes or cationic amphiphile-virus complexes may be formulated into
15 compositions for administration to an individual in need of the delivery of the transgenes.

The compositions can include physiologically acceptable carriers, including any relevant solvents. As used herein, "physiologically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents,
20 isotonic and absorption delaying agents, and the like. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the compositions is contemplated.

Routes of administration for the compositions containing the chimeric adenoviral vectors of the invention include conventional and physiologically
25 acceptable routes such as direct delivery to a target organ or tissue, intranasal, intravenous, intramuscular, subcutaneous, intradermal, oral and other parenteral routes of administration.

The invention is further directed to methods for using the compositions of the invention in vivo or ex vivo applications in which it is desirable to deliver one or more

- 19 -

transgenes into cells such that the transgene produces a biologically active protein for a normal biological or phenotypic effect. In vivo applications involve the direct administration of one or more chimeric adenoviral vectors formulated into a composition to the cells of an individual. Ex vivo applications involve the transfer of
5 a composition containing the chimeric adenoviral vectors directly to autologous cells which are maintained in vitro, followed by readministration of the transduced cells to a recipient.

Dosage of the chimeric adenoviral vector to be administered to an individual for expression of a transgene encoding a biologically active protein and to achieve a
10 specific phenotypic result is determined with reference to various parameters, including the condition to be treated, the age, weight and clinical status of the individual, and the particular molecular defect requiring the provision of a biologically active protein. The dosage is preferably chosen so that administration causes a specific phenotypic result, as measured by molecular assays or clinical markers. For
15 example, determination of the infection efficiency of a chimeric adenoviral vector containing the CFTR transgene which is administered to an individual can be performed by molecular assays including the measurement of CFTR mRNA, by, for example, Northern blot, S1 or RT-PCR analysis or the measurement of the CFTR protein as detected by Western blot, immunoprecipitation, immunocytochemistry, or
20 other techniques known to those skilled in the art. Relevant clinical studies which could be used to assess phenotypic results from delivery of the CFTR transgene include PFT assessment of lung function and radiological evaluation of the lung. Demonstration of the delivery of a transgene encoding CFTR can also be demonstrated by detecting the presence of a functional chloride channel in cells of an
25 individual with cystic fibrosis to whom the vector containing the transgene has been administered (Zabner et al., J. Clin. Invest. 97:1504-1511, 1996). Transgene expression in other disease states can be assayed analogously, using the specific clinical parameters most relevant to the condition.

- 20 -

Dosages of a chimeric adenoviral vector which are effective to provide expression of a transgene encoding a biologically active protein and achieve a specific phenotypic result range from approximately 10^8 infectious units (I.U.) to 10^{11} I.U. for humans.

5 It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated, each unit containing a predetermined quantity of active ingredient calculated to produce the specific phenotypic effect in association with the required
10 physiologically acceptable carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly depend on the unique characteristics of the chimeric adenoviral vector and the limitations inherent in the art of compounding. The principal active ingredient (the chimeric adenoviral vector) is compounded for convenient and effective administration in effective amounts with the physiologically
15 acceptable carrier in dosage unit form as discussed above.

Maximum benefit and achievement of a specific phenotypic result from administration of the chimeric adenoviral vectors of the invention may require repeated administration. Such repeated administration may involve the use of the same chimeric adenoviral vector, or, alternatively, may involve the use of different
20 chimeric adenoviral vectors which are rotated in order to alter viral antigen expression and decrease host immune response.

The practice of the invention employs, unless otherwise indicated, conventional techniques of protein chemistry, molecular virology, microbiology, recombinant DNA technology, and pharmacology, which are within the skill of the
25 art. Such techniques are explained fully in the literature. See, e.g., Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, Inc., New York, 1995, and Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, PA, 1985.

- 21 -

The invention is further illustrated by the following specific examples which are not intended in any way to limit the scope of the invention.

Examples

5

Example 1 Infection of NHBE cells by adenovirus serotypes of subgroup D

Normal human bronchial epithelial ("NHBE") cells were obtained from Clonetics (San Diego, CA), and plated on Costar (Cambridge, MA) Transwell-Clear polyester membranes that were pre-coated with human placental collagen. The wells
10 were placed in a cluster plate and cells were fed every day for one week by changing the medium in both the well and the plate. After one week the media was removed from the wells to create an air-liquid interface, and the cells were then fed only by changing the medium in the cluster plate, every other day for one week. Cells were
15 infected at an moi of 1 by adding virus (see below) to the transwell, followed by an incubation time of 1.5-2 hours. At the end of the incubation period, the medium was removed and the cells were gently rinsed with fresh medium. Thirty-six hours post-infection the cells were fixed with 1:1 acetone:methanol, permeablized with a solution of 0.05% Tween 20 in PBS, and stained with FITC labeled anti-hexon antibody (Chemicon, Temecula, CA) to visualize cells that had been productively infected (i.e.
20 to visualize virus replication). Cells were also subjected to the DAPI staining procedure in order to visualize the total number of nuclei. The results could be readily determined upon simple inspection.

Wild type Ad serotypes within subgroup D that were tested included 9, 15, 17, 19, 20, 22, 26, 27, 28, 30, and 39 (all from the American Type Culture Collection,
25 Rockville, MD). An Ad 2 (obtained as DNA from BRL, Gaithersburg, MD, and used to transfect 293 cells in order to generate virus stock) was used as a control. Infection observed with all of the subgroup D serotypes was superior to that observed with Ad 2, with the best results being achieved with Ad 9, Ad 17, Ad 20, Ad 22, and Ad 30.

- 22 -

Additionally, it was determined that each of the above-mentioned serotypes of subgroup D was more effective in the NHBE cell assay under similar circumstances than any other serotype tested than belongs to a subgroup other than D. In this regard, the following serotypes were also tested: 31(subgroup A); 3(subgroup B); 7(subgroup B); 7a(subgroup B); 14(subgroup B); 4(subgroup E); and 41(subgroup F). In a further experiment, serotype 35 (subgroup A) may have performed as well as the least effective members of subgroup D that were tested.

Example 2 Infection of clinical isolate bronchial epithelial cells

10 Following generally the procedures of Example 1, human bronchial epithelial cells recovered from healthy human volunteers were infected with either Ad 2 (as above, Ad 2 DNA was obtained from BRL, and this DNA was used to transfect 293 cells to generate virus) (Figure 1), or Ad 17 (from ATCC) (Figure 2), all at an moi of 50. Cells were left in contact with virus for 30 minutes, 3 hours, or 12 hours.

15 The increased tropism of Ad 17 for human bronchial epithelial cells, compared with Ad 2, is readily apparent upon inspection of Figures 1 and 2. In the Figures, the right hand columns (panels D, E, and F, stained in blue) show total numbers of cells present (from DAPI staining as above), whereas the left hand columns (panels A, B, and C, stained in green) quantify adenovirus hexon protein present in the infected cells
20 (from FITC-labeled anti-hexon antibody, as above). Panels A and D result from 30 minute incubation times, panels B and E result from 3 hour incubation times, and panels C and F result from 12 hour incubation times. As measured by the technique employed, infection of airway epithelia by Ad 17 is at least 50 fold greater than by Ad 2 for the thirty minute incubation time.

25

Example 3 Binding of Ad 2 and Ad 17 to human nasal polyp cell isolates

293 cells, a complementing cell line developed by Graham et al. (see Gen. Virol. , 36, 1977, pp. 59-72), were infected with either wild type Ad 2 or wild type Ad 17. Five hours post-infection the media was removed and replaced with methionine

- 23 -

free media containing S^{35} metabolic label (Amersham). After an additional six hours, fresh media was added and the labeling was allowed to proceed for a total of 18 hours, after which the S^{35} media was removed and replaced with fresh media. Thirty hours post-infection the cells were harvested and lysed and the labeled Ad 2 or Ad 17
5 viruses were purified by CsCl gradient centrifugation. The recovered viruses were then used in an assay to determine their relative binding efficiency on human nasal polyp cells.

In order to perform the assay, ciliated human airway epithelial cells were recovered from nasal polyps of healthy volunteers. The results from two such isolates,
10 NP-14 and NP-15, are reported here (see Figure 3). Radiolabeled virus was then incubated with the isolated cells in wells for specified times (5 or 30 minutes, see Figure 3). The cells were then rinsed and measured for radioactivity. Binding as reported in Figure 3 indicates the percent of input radioactivity that is cell associated. It was determined that for both cell isolate populations, using either 5 or 30 minute
15 incubations, cell associated radioactivity was 10-fold enhanced if Ad 17 rather than Ad 2 was used.

Example 4 Fiber competition

20 A549 cells (a human lung carcinoma line, obtained from the American Type Culture Collection as ATCC CCL-185) were plated at 3×10^4 cells per well in 96-well dishes. Since the number of receptor sites for adenovirus fiber on the cell surface has been estimated to be approximately 10^5 receptors per cell, the receptors in the plated cells were saturated, in this example, with $0.1 \mu\text{g}$ of purified full length Ad 2 fiber
25 protein (obtained from Paul Freimuth, Brookhaven National Laboratory, Upton, NY), which corresponds to approximately 100 molecules of fiber per receptor. Cells were incubated with Ad 2 fiber in PBS for two hours at 37°C .

- 24 -

The cells were subsequently infected at an moi of 1 (using either Ad 2 provided as above, or wild type Ad 17) for one hour, after which the cells were rinsed, and fresh medium was added. Control cultures were incubated with PBS with no added protein for two hours and then subsequently infected as described above. Forty
5 hours post-infection the cells were fixed with 1:1 acetone:methanol, permeabilized with 0.05% Tween 20 in PBS and stained with FITC labeled anti- Ad 2 hexon antibody, as described in Example 1. As determined by this assay, the number of cells infected (stained) with Ad 2 was reduced by approximately 90% in cultures that were pre-incubated with Ad 2 fiber as compared to control cultures. However, no effect on
10 Ad 17 infection was observed by the pre-incubation of A549 cells with full length Ad 2 fiber.

Example 5 Use of Ad 2 fiber knob in a binding competition
experiment with Ad 2

15

Further competition experiments were performed with Ad 2 and Ad 17 fiber knobs that had been expressed and purified from *E. coli*. DNA sequences encoding both protein fragments were designed so that the fiber knobs expressed therefrom would contain histidine tags in order to permit nickel- column purification. The yield
20 of soluble fiber knob trimer, purified by the Ni-NTA method (Qiagen, Chatsworth, CA), was ~25µg/50ml culture. A significant portion of the total knob protein expressed appeared to remain in a monomeric (and insoluble) form. The soluble trimeric material obtained was used for a preliminary competition experiment. Wild type Ad 2 and Ad 17 were used to infect A549 cells, or cells that had been pre-
25 incubated with excess (about 100 molecules of trimer per receptor) Ad 2 fiber knob or Ad 17 fiber knob. The results indicated that Ad 2 fiber knob, but not Ad 17 knob, could block Ad 2 infection. Additionally, Ad 17 infection was not blocked by *E. coli*-expressed fiber knobs of either serotype, suggesting that the mechanism of Ad 2 and Ad 17 infections is different.

- 25 -

Example 6 Construction of the chimeric vector Ad2/ β gal-2/fiber Ad 17

The vector Ad2/ β gal-2 was constructed as follows. A CMV β gal expression
5 cassette was constructed in a pBR322-based plasmid that contained Ad 2 nucleotides
1-10,680 from which nucleotides 357-3328 were deleted. The deleted sequences were
replaced with (reading from 5' to 3'): a cytomegalovirus immediate early promoter
(obtained from pRC/CMV, Invitrogen), lacZ gene encoding β -galactosidase with a
nuclear localization signal, and an SV40 polyadenylation signal (nucleotides 2533-
10 2729). The resulting plasmid was used to generate Ad2/ β gal-2 by recombination with
Ad2E4ORF6 (D. Armentano et al., Human Gene Therapy , 6, 1995, pp 1343 -1353).

A chimeric Ad2/ β gal-2/fiber Ad 17 viral vector (Figure 4) was then constructed
as follows. pAdORF6 (D. Armentano et al., Human Gene Therapy , 6, 1995, pp 1343
-1353) was cut with Nde and BamHI to remove Ad 2 fiber coding and polyadenylation
15 signal sequences (nucleotides 20624-32815). An NdeI-BamHI fragment containing
Ad 17 fiber coding sequence (nucleotides 30984-32095) was generated by PCR and
ligated along with an SV40 polyadenylation signal into NdeI-BamHI cut pAdORF6 to
generate pAdORF6fiber17. This plasmid was cut with PacI and then ligated to PacI-
cut Ad2/ β gal-2 DNA to generate Ad2/ β gal-2fiber 17. Any desired transgene may be
20 substituted in this construct for the reporter gene.

A similar construct can be prepared using a DNA sequence that encodes Ad 17
penton base instead of Ad 17 fiber. Alternatively, only a subregion of the penton base
of Ad 2 need be subject to replacement, such as by inserting into the vector a
nucleotide encoding sequence corresponding to any amino acid subsequence of Ad 17
25 penton base amino acids 283-348 (see the marked sequence in Figure 5A) in
replacement for any subsequence of Ad 2 penton base amino acids 290-403.
Preferrably, the replaced sequence of Ad 2 and the inserted sequence of Ad 17
includes the RGD domain of each. Use of nucleotide sequence corresponding to
penton base amino acid sequence for other subgroup D serotypes is also within the

- 26 -

practice of the invention. It is also within the scope of the invention to replace a subregion of the fiber protein in the Ad 2 vector with a subregion from another adenovirus serotype, for example, Ad 17.

5 Example 7 Ad2/ β gal-2f17 shows increased infection efficiency on human airway explants

Both human and monkey trachea explants, about 1 cm², were placed on top of an agar support. Each explant was infected at an moi of 200 of either Ad2/ β gal-2 or Ad2/ β gal-2f17 assuming a cell density of 1 x 10⁶ per cm² of explant. Explants were
10 exposed to virus for three hours and were then rinsed with NHBE media. Two days post-infection explants were stained with X-gal and infection efficiency was assessed. On the monkey explants Ad2/ β gal-2 gave rise to a higher infection efficiency than Ad2/ β gal-2f17. Patches of stained cells were detected in explants exposed to Ad2/ β gal-2 but very few cells stained in explants exposed to Ad2/ β gal-2f17. A
15 different result was obtained on human trachea explants. On these explants Ad2/ β gal-2f17 infection gave rise to a much higher infection efficiency than Ad2/ β gal-2 infection. Approximately 5-10% of the cells in explants exposed to Ad2/ β gal-2f17 stained with X-gal whereas very few cells were stained in explants exposed to Ad2/ β gal-2. No background staining was observed in either monkey or human
20 explants that were not exposed to virus.

The results indicate that the exchange of Ad 2 fiber for Ad 17 fiber in Ad2/ β gal-2f17 was sufficient to significantly increase infection efficiency of human tracheal airway cells by an adenovirus type 2 based vector.

25 Example 8 Adenovirus subgroup screening on human cancer cell lines

Identification of adenovirus subgroup that best infects a particular tumor type may be useful in designing vectors to optimally target cancer cells in vivo. In order to determine the adenovirus subgroup that best infects a particular type of cancer cell, cancer cells were seeded into a 96 well plate and infected with an moi of 5. Infection

- 27 -

efficiency was determined by staining of infected cells using an anti-hexon antibody. The adenovirus subgroups were represented by the following serotypes: A: Ad 31; B: Ad 3; C: Ad 2; D: Ad 17; E: Ad 4; and F: Ad 41.

Subgroup D (Ad 17) has a significantly higher infection rate of the colon
5 cancer cell line CaCo-2 than other cell types, with an infection rate of 70%, while Ad 2 only infected 20% of the cells (Figure 9).

Subgroup D (Ad 17) was effective in infecting ovarian cancer cell line SK-OV3. Infection was measured at 90% (Figure 10).

10 Sequence Listing

Included herewith on the following pages are informal copies of SEQ ID NO: 1 through SEQ ID NO: 3.

1 CATCATCAAT AATATACCCC ACAAAGTAAA CAAAAGTTAA TATGCAAATG AGGTTTTTAAA
 61 TTTAGGGCGG GGCTACTGCT GATTGGCCGA GAAACGTTGA TGCAAATGAC GTCACGACGC
 121 ACGGCTAACG GTCGCCGCGG AGGCGTGGCC TAGCCCGGAA GCAAGTCGCG GGGCTGATGA
 181 CGTATAAAAA AGCGGACTTT AAACCCGGAA ACGGCCGATT TTCCCGCGGC CACGCCCGGA
 241 TATGAGGTAA TTCTGGGCGG ATGCAAGTGA AATTAGGTCA TTTTGGCGCG AAAACTGAAT
 301 GAGGAAGTGA AAAGTGAAAA ATACCGGTCC CGCCAGGGC GGAATATTTA CCGAGGGCCG
 361 AGAGACTTTG ACCGATTACG TGTGGGTTTC GATTGCGGTG TTTTTCGCG AATTTCCGCG
 421 TCCGTGTCAA AGTCCGGTGT TTATGTCACA GATCAGCTGA TCCACAGGGT ATTTAAACCA
 481 GTCGAGCCCG TCAAGAGGCC ACTCTTGAGT GCCAGCGAGT AGAGATTTCT CTGAGCTCCG
 541 CTCCAGAGT GTGAGAAAAA TGAGACACTT GCGCCTCCTG CCTGGAAC TGCCCTTGGA
 601 CATGGCCGCA TTATTGCTGG ATGACTTTGT GAGTACAGTA TTGGAGGATG AACTGCAACC
 661 AACTCCGTTT GAGCTGGGAC CCACACTTCA GGACCTCTAT GATTTGGAGG TAGATGCCCA
 721 GGAGGACGAC CCGAACGAAG ATGCTGTGAA TTTAATATTT CCAGAATCTC TGATTCTTCA
 781 GGCTGACATA GCCAGCGAAG CTCTACCTAC TCCACTTCAT ACTCCAATC TGTCACCCAT
 841 ACCTGAATTG GAAGAGGAGG ACGAGTTAGA CCTCCGGTGT TATGAGGAAG GTTTTCCTCC
 901 CAGCGATTCA GAGGACGAAC AGGGTGAGCA GAGCATGGCT CTAATCTCAG ACTATGCTTG
 961 TGTGGTTGTG GAAGAGCATT TTGTGTGGGA CAATCCTGAG GTGCCCGGGC AAGGCTGTAA
 1021 ATCCTGCCAG TACCACCGGG ATAAGACCGG AGACACGAAC GCCTCCTGTG CTCTGTGTTA
 1081 CATGAAAAAG AACTTCAGCT TTATTACAG TAAGTGGAGT GAATGTGAGA GAGGCTGAGT
 1141 GCTTAAGACA TAACTGGGTG ATGCTTCAAC AGCTGTGCTA AGTGTGGTTT ATTTTGTTC
 1201 TAGGTCCGGT GTCAGAGGAT GGTATCACC CTCAGAAGAA GACCACCGT GTCCCCCTGA
 1261 TCTGTCAGG GAAACGCCCC TGCAAGTGCA CAGACCCACC CCAGTCAGAC CCAGTGGCGA
 1321 GAGGCGAGCA GCTGTGAAA AAATTGAGGA CTTGTTACAT GACATGGGTG GGGATGAACC
 1381 TTTGGACCTG AGCTTGA AAC GTCCCAGGAA ACTAGGCGCA GCTGCGCTTA GTCATGTGTA
 1441 AATAAAGTTG TACAATAAAA ATTATATGTG ACGCATGCAA GGTGTGGTTT ATGACTCATG
 1501 GGCGGGGCTT AGTTCTATAT AAGTGGCAAC ACCTGGGCAC TGGAGCACAG ACCTTCAGGG
 1561 AGTTCTGAT GGATGTGTG ACTATCCTTG CAGACTTTAG CAAGACACGC CGGCTTGATG
 1621 AGGATAGTTC AGACGGGTGC TCCGGTTCT GGAGACACTG GTTTGGAAC CTCTATCTC
 1681 GCCTGGTGTA CACAGTTAAA AAGGATTATA ACGAGGAATT TGAAAATCTT TTTGCTGATT
 1741 GCTCTGGCCT GCTAGATTCT CTGAATCTCG GCCACCAAGT CCTTTTCCAG GAAAGGGTAC
 1801 TCCACAGCCT TGATTTTTC AGCCCAGGGC GCACTACAGC CGGGGTGCT TTTGTGGTTT
 1861 TTCTGGTTGA CAAATGGAGC CAGAACACCC AACTGAGCAG GGGCTACATT CTGGACTTCG
 1921 CAGCCATGCA CCTGTGGAGG GCATGGGTCA GGCAGCGGG ACAGAGAATC TTGAACACT
 1981 GGCTTCTACA GCCAGCAGCT CCGGTCTTC TTCGTCTACA CAGACAAACA TCCATTTGG
 2041 AGGAAGAAAT GAGGCAAGCC ATGGACGAGA ACCCGAGGAG CCGTCTGGAC CCTCCGTCG
 2101 AAGAGGAGTT GGATTGAATC AGGTATCCAG CCTGTACCCA GAGCTTAGCA AGGTGCTGAC
 2161 ATCCATGGCC AGGGGAGTGA AGAGGGAGAG GAGCGATGGG GGCAATACCG GGATGATGAC
 2221 CGAGCTGACG GCCAGTCTGA TGAATCGCAA GCGCCAGAG CGCCTTACCT GGTACGAGCT
 2281 ACAGCAGGAG TGCAGGGATG AGTTGGGCTT GATGCAGGAT AAATATGGCC TGGAGCAGAT
 2341 AAAAACCCAT TGGTTGAACC CAGATGAGGA TTGGGAGGAG GCTATTAGA AGTATGCCAA
 2401 GATAGCCCTG CGCCAGATT GCAAGTACAT AGTGACCAAG ACCGTGAATA TCAGACATGC
 2461 TGCTACATCT CGGGGAACGG GGCAGAGGTG GTCATTGATA CCCTGGACAA GGCCGCTTT
 2521 AGGTGTTGCA TGATGGGAAT GAGAGCCGGA GTGATGAATA TGAATTCAT GATCTTTATG
 2581 AACATGAAGT TCAATGGAGA GAAGTTTAA TGGGTGCTGT TCATGGCCAA CAGCCACATG
 2641 ACCCTGCATG GCTGCGACTT TTTCCGCTTT AACAATATGT GCGCAGAGGT CTGGGGCGCT
 2701 TCCAAGATCA GGGGATGTAA GTTTTATGGC TGCTGGATGG GCGTGGTCGG AAGACCCAAG
 2761 AGCGAGATGT CTGTGAAGCA GTGTGTGTTT GAGAAATGCT ACCTGGGAGT CTCTACCGAG
 2821 GGCAATGCTA GAGTGAGGCA CTGCTCTTCC CTGGAGACGG GCTGCTTCTG CCTGGTGAAG
 2881 GGCACAGCCT CTCTGAAGCA TAATATGGTG AAGGGCTGCA CGGATGAGCG CATGTACAAC
 2941 ATGCTGACTG CGACTCGGGG GTCTGTCATA TCCTGAAGAA CATCCATGTG ACCTCCACC
 3001 CCAGAAAGAA GTGGCCAGTG TTTGAGAATA ACATGCTGAT CAAGTGCCAC ATGCACCTGG
 3061 GCGCCAGAAG GGGCACCTTC CAGCCGTACC AGTGCAACTT TAGCCAGACC AAGCTGCTGT
 3121 TGGAGAACGA TGCTTCTCC AGGGTGAACC TGAACGCAT CTTTGACATG GATGTCTCG
 3181 TGTACAAGAT CCTGAGATAC GATGAGACCA AGTCCAGGGT GCGCGCTTGC GAGTGCGGGG
 3241 GCAGACACAC CAGGATGCAG CCAGTGGCCC TGGATGTGAC CGAGGAGCTG AGACCAGACC
 3301 ACCTGGTGAT GGCCTGTACC GGGACCGAGT TCAGCTCCAG TGGGGAGGAC ACAGATTAGA
 3361 GGTAGGTTTG AGTAGTGGGC GTGGCTAAGG TGACTATAAA GGCGGGTGTC TTACGAGGGT

3421 CTTTTTGCTT TTCTGCAGAC ATCATGAACG GGACCGGCGG GGCCTTCGAA GGGGGGCTTT
3481 TTAGCCCTTA TTTGACAACC CGCCTGCCAG GATGGGCGCG AGTTCGTCAG AATGTGATGG
3541 GATCGACGGT GGACGGGCGC CCAGTGCTTC CAGCAAATTC CTCGACCATG ACCTACGCGA
3601 CCGTGGGGAA CTCGTCGCTT GACAGCACC GCGCAGCCGC GGCAGCCGCA CCCGCCATGA
3661 CAGCGACGAG ACTGGCCTCG AGCTACATGC CCAGCAGCAG CAGTAGCCCC TCTGTGCCCA
3721 GTTCCATCAT CGCCGAGGAG AACTGCTGGC CTTGCTGGCC GAGCTGGAAG CCCTGAGCCG
3781 CCAGCTGGCC GCCCTGACCC AGCAGGTGTC CGAGCTCCGC GAACAGCAGC AGCAAAATAA
3841 ATGATTCAAT AAACACATAT TCTGATTCAA ACAGCAAAGC ATCTTTATTA TTTATTTTTT
3901 CGCGCGCGGT AGGCCCTGGT CCACCTCTCC CGATCATTGA GAGTGCCTGT GATTTTTTCC
3961 AAGACCCGGT AGAGGTGGGA TTGGATGTTG AGGTACATGG GCATGAGCCC GTCCCGGGGG
4021 TGGAGGTAGC ACCACTGCAT GGCCTCGTGC TCTGGGGTCG TGTGTAGAT GATCCAGTCA
4081 TAGCAGGGGC GCTGGGCGTG GTGCTGGATG ATGTCTTGA GGAGGAGACT GATGGCCACG
4141 GGGAGCCCTT TGGTGTAGGT GTTGGCAAAG CGTTGAGCT GGGAGGGATG CATGCGGGGG
4201 GAGATGATGT GCAGTTTGGC CTGGATCTTG AGGTTGGCGA TGTGCCCACC CAGATCCCGC
4261 CGGGGGTTC A TGTGTGTCAG GACCACCAGG ACGGTGTAGC CCGTGCCTT GGGGAACCTA
4321 TCATGCAACT TGAAGGGAA TGCCTGGAAG AATTTGGAGA CGCCCTTGTG CCCGCCCAGG
4381 TTTTCCATGC ACTCATCCAT GATGATGGCG ATGGGCCCCT GGGCTGCGGC TTTGGCAAAG
4441 ACGTTTCTGG GGTGAGAGAC ATCATAATTA TGCTCCTGGG TGAGATCATC ATAAGACATT
4501 TTAATGAATT TTGGGCGGAG GGTGCCAGT TGGGGGACGA TGGTTTCCCT CGGGCCCCGG
4561 GCGAAGTTC CCCTCGCAGA TCTGCATCTC CCAGGCTTTC ATCTCGGAGG GGGGGATCAT
4621 GTCCACCTTG GGGGCGATGA AAAAAACGGT TTCCGGGGCG GGGGTGATGA GCTGCGAGGA
4681 GAGCAGGTTT CTCAACAGCT GGGACTTGCC GCACCCGGTC GGGCCGTAGA TGACCCCGAT
4741 GACGGGTTGC AGGTGGTAGT TCAAGGACAT GCAGCTGCCG TCGTCCCGGA GGAGGGGGGC
4801 CACCTCGTTG AGCATGTCTC TAACTTGGAG GTTTTCCCGG ACGAGCTCGC CGAGGAGGCG
4861 GTCCCGCCCC AGCGAGAGGA GCTCTTGACG GGAAGCAAAG TTTTTCAGGG GCTTGAGTCC
4921 GTCGGCCATG GGCATCTTGG CGAGGGTCTG CGAGAGGAGT TCGAGACGTC CCAGAGCTCG
4981 GTGACGTGCT CTACGGCATC TCGATCCAGC AGACTTCCTC GTTTCGGGGG TTGGGACGAC
5041 TGCGACTGTA GGGCAGGAGA CGATGGGCGT CCAGCGCGGC CAGCGTCATG TCCTTCCAGG
5101 GTCTCAGGGT CCGCGTGAGG GTGGTCTCCG TCACGGTGAA GGGGTGGGCC CCTGGCTGGG
5161 CGCTTGCAAG GGTGCGCTTG AGACTCATCC TGCTGGTGCT GAAACGGGCA CGGTCTTCGC
5221 CTTGCGCGTC GCGGAGATAG CAGTTGACCA TGAGCTCGTA GTTGAGGGCC TCGGCGGCGT
5281 GGCCCTTGGC GCGGAGCTTG CCCTTGGAAG AGCGTCCGCA GGCGGGACAG AGGAGGGATT
5341 GCAGGGCGTA GAGCTTGGGC GCAAGAAAGA CCGACTCGGG AGCAAAAGCG TCCGCTCCGC
5401 AGTGGGCGCA GACGGTCTCG CACTCGACGA GCCAGGTGAG CTCGGGCTGC TCGGGGTCAA
5461 AAACCAAGTT TCCCCGTTT TTTTGTATGC GCTTCTTACC TCGCGTCTCC ATGAGTCTGT
5521 GTCCGCGCTC GGTGACAAAC AGGCTGTCCG TGTCCCGTA GACGGACTTG ATTGGCCTGT
5581 CCTGCAGGGG CGTCCCGCGG TCCTCTCTCG AGAGAACTC GGACCACTCT GAGACAAAGG
5641 CGCGCGTCCA CGCCAAGACA AAGGAGGCCA CGTGCAGGG GTAGCGGTG TGTCCACCA*
5701 GGGGGTCCAC CTTTTCCACC GTGTGCAGAC ACATGTCCCC TTCTCCGCA TCCAAGAAGG
5761 TGATTGGCTT GTAGGTGTAG GCCACGTGAC CAGGGTCCC CGACGGGGGG GTATAAAAGG
5821 GGGCGGGTCT GTGCTCGTCC TCACTCTCTT CCGCGTCCGT GTCCACGAGC GCCAGCTGTT
5881 GGGGTAGGTA TTCCCTCTCG AGAGCGGGCA TGACCTCGGC ACTCAGGTTG TCAGTTTCTA
5941 GAAACGAGGA GGATTTGATG TTGGCTTGCC CTGCGCAAT GCTTTTATAG AGACTTTCAT
6001 CCATCTGGTC AGAAAAGACT ATTTTTTTAT TGTCAAGCTT GGTGGCAAAG GAGCCATAGA
6061 GGGCGTTGGA GAGAAGCTTG GCGATGGATC TCATGGTCTG ATTTTGTCA CGGTCCGCGC
6121 GCTCCTTGGC CGCGATGTTG AGCTGGACAT ATTCGCGCGC GACACACTTC CATTCCGGAA
6181 AGACGGTGGT GCGCTCGTCC GGCACGATCC TGACGCGCCA GCCGCGGTTA TGCAGGGTGA
6241 CCAGGTCCAC GCTGGTGGCC ACCTCGCCGC GCAGGGGCTC GTTAGTCCAG CAGAGTCTGC
6301 CGCCCTTGGC CGAGCAGAAC GGGGGCAGCA CATCAAGCAG ATGCTCGTCA GGGGGTCCG
6361 CATCGATGGT GAAGATGCCG GGACAGAGTT TCTGTCAAA ATAGTCTATT TTTGAGGATG
6421 CATCATCCAA GGCCATCTGC CACTCGCGGG CGGCCATTGC TCGCTCGTAG GGGTTGAGGG
6481 GCGGACCCCA CGGCATGGGA TGCGTGAGGG CGGAGGCGTA CATGCCGAA ATGTGCTAAA
6541 CATAGATGGG CTCCGAGAAG ATGCCGATGT TGGTGGGATA ACAGCGCCCC CCGCGGATGC
6601 TGGCGCGCAC GTATTATAC AACTCGTGCG AGGGGCCAAG AAGGCCGGGG CCGAAATTGG
6661 TGCGCTGGGG CTGCTCGGCG CGGAAAACAA TCTGGCGAAA GATGGCGTGC GAGTTGGAGG
6721 AGATGGTGGG CCGTTGGAAG ATGTTAAAGT GGGCGTGGGG CAAGCGGACC GAGTCGCGGA
6781 TGAAGTGCGC GTAGGAGTCT TGCAGCTTGG CGACGAACTC GGCGGTGACC AGAACGTCCA

6841	TGGCGCAGTA	GTCCAGCGTT	TCGCGGATGA	TGTCATAACC	CGCCTCTCCT	TTCTTCTCCC
6901	ACAGCTCGCG	GTTGAGGGCG	TATTCCTCGT	CATCCTTCCA	GTACTCCCGG	AGCGGGAATC
6961	CTCGATCGTC	CGCACGGTAA	GAGCCCAGCA	TGTAGAAATG	GTTACACGCC	TTGTAGGGAC
7021	AGCAGCCCTT	CTCCACGGGG	AGGGCGTAAG	CTTGTGCGGC	CTTGCGGAGC	GAGGTGTGCG
7081	TCAGGGCGAA	GGTGTCCCTG	ACCATGACTT	TCAAGAAGTG	GTACTTGAAA	TCCGAGTCGT
7141	CGCAGCCGCC	GTGCTCCCAT	AGCTCGAAAT	CGGTGCGCTT	CTTCGAGAGG	GGGTTAGGCA
7201	GAGCGAAAGT	GACGTCATTG	AAGAGAATCT	TGCCTGCTCG	CGGCATGAAA	TTGCGGGTGA
7261	TGCGGAAAGG	GCCCGGGACG	GAGGCTCGGT	TGTTGATGAC	CTGGGCGGCG	AGGACGATCT
7321	CGTCGAAGCC	GTTGATGTTG	TGCCCCAGCA	TGTAGAGTTC	CATGAATCGC	GGGCGGCCCT
7381	TGATGTGCGG	CAGCTTTTTG	AGCTCCTCGT	AGGTGAGGTC	CTCGGGGCAT	TGCAGGCCGT
7441	GCTGCTCGAG	CGCCCATTCC	TGGAGATGTG	GGTTGGCTTG	CATGAAGGAA	GCCCAGAGCT
7501	CGCGGGCCAT	GAGGGTCTGG	AGCTCGTCGC	GAAAGAGGCG	GAAGTGTCTG	CCACCGGCCA
7561	TCTTTTCGGG	TGTGACGCAG	TAGAAGGTGA	GGGGGTCCCG	CTCCCAGCGA	TCCCAGCGTA
7621	AGCGCGCGGC	TAGATCGCGA	GCAAGGGCGA	CCAGCTCTGG	GTCCCCCGAG	AATTTTCATGA
7681	CCAGCATGAA	GGGGACGAGC	TGCTTGCCGA	AGGACCCCAT	CCAGGTGTAG	GTTTCTACAT
7741	CGTAGGTGAC	AAAGAGCCGC	TCCGTGCGAG	GATGAGAGCC	GATTGGGAAG	AAC TGGATT
7801	CCTGCCACCA	GTTGGACGAG	TGGCTGTTGA	TGTGATGAAA	GTAGAAATCC	CGCCGCGGAA
7861	CCGAGCACTC	GTGCTGATGC	TTGTAAAAGC	GTCCGCAGTA	CTCGCAGCGC	TGCCAGGGCT
7921	GTACCTCATC	CACGAGATAC	ACAGCGCGTC	CCTTGAGGAG	GAAGTTCAGG	AGTGGCGGCC
7981	CTGGCTGGTG	GTTTTCATGT	TCGCCTGCGT	GGGACTCACC	CTGGGGCTCC	TCGAGGACGG
8041	AGAGGCTGAC	GAGCCCGCGC	GGGAGCCAGG	TCCAGATCTC	GGCGCGGCGG	GGGCGGAGAG
8101	CGAAGACGAG	GGCGCGCAGT	TGGGAGCTGT	CCATGGTGTC	GCGGAGATCC	AGGTCCGGGG
8161	GCAGGGTTCT	GAGGTTGACC	TCGTAGAGGC	GGGTGAGGGC	GTGCTTGAGA	TGCAGATGGT
8221	ACTTGATTTC	TACGGGTGAG	TTGGTGGCCG	TGTCCACGCA	TTGCATGAGC	CCGTAGCTGC
8281	GCGGGGCCAC	GACCGTGCCG	CGGTGCGCTT	TTAGAAGCGG	TGTGCGGGAC	GCGCTCCCGG
8341	CGGCAGCGGC	GGTTCCGGCC	CCGCGGGCAG	GGGCGGCAGA	GGCACGTCCG	CGTGGCGCTC
8401	GGGCAGGTCC	CGGTGTTGCG	CCCTGAGAGC	GCTGGCGTGC	GCGACGACGC	GGCGGTTGAC
8461	ATCCTGGATC	TGCCGCTCT	CGGTGAAGAC	CACTGGCCCC	GTGACTTTGA	ACCTGAAAGA
8521	CAGTTCAACA	GAATCAATCT	CGGCGTCATT	GACGGCGGGC	TGACGCAGGA	TCTCTTGAC
8581	GTCGCCCCAG	TTGTCTTGGT	AGGCGATCTC	GGACATGAAC	TGCTCGATCT	CCTCCTCCTG
8641	GAGATCGCCG	CGACCCGCGC	GCTCCACGGT	GGCGGCGAGG	TCATTTCGAGA	TCCGACCCAT
8701	GAGCTGCGAG	AAGGCGCCCA	GGCCGCTCTC	GTTCCAGACG	CGGCTGTAGA	CCACGTCCCC
8761	GTCGGCGTCG	CGCGCGCGCA	TGACCACCTG	CGCGAGGTTG	AGCTCCACGT	GCCGCGCGAA
8821	GACGCGTAG	TTGCGCAGGC	GCTGGAAGAG	GTAGTTGAGG	GTGGTGGCGA	TGTGCTCGGT
8881	GACGAAGAAG	TACATGATCC	AGCGGCGCAG	GGGCATCTCG	CTGATGTCCG	CGATGGCCTC
8941	CAGCCTTTCC	ATGGCCTCGT	AGAAATCCAC	GGCGAAGTTG	AAAAACTGGG	CGTTGCGGGC
9001	CGAGACCGTG	AGCTCGTCTT	CCAGGAGCCT	GATGAGCTCG	GCGATGGTGG	CGCGCACCTC
9061	GCGTTCGAAA	TCCCCGGGGG	CCTCGTCTCT	TTCTCTTTCT	TCCATGACAA	CCTCTTCTAT
9121	TTCTTCCTCT	GGGGGCGGTG	GTGGTGGCGG	GGCCCCACGA	CGACGGCGAC	GCACCGGGAG
9181	ACGGTCGACG	AAGCGCTCGA	TCATCTCCCC	GCGGCGGCGA	CGCATGGTTT	CGGTGACGGC
9241	GCGACCCCGT	TCGCGAGGAC	GCAGCGTGAA	GACGCCGCCG	GTCATCTCCC	GGTAATGGGG
9301	CGGGTCCCCG	TTGGGCAGCG	AGAGGGCGCT	GACGATGCAT	CTTATCAATT	GCGGTGTAGG
9361	GGACGTGAGC	GCGTCGAGAT	CGACCCGATC	GGAGAATCTT	TCGAGGAAAG	CGCTAGCCA
9421	ATCGCAGTCG	CAAGGTAAGC	TCAAACACGT	AGCAGCCCTG	TGGACGCTGT	TAGAATTGCG
9481	GTTGCTAATG	ATGTAATTGA	AGTAGGCGTT	TTTGAGGCGG	CGGATGGTGG	CGAGGAGGAC
9541	CAGGTCCCTT	GGTCCCGCTT	GCTGGATGCG	GAGCCGCTCG	GCCATGCCCC	AGGCCTGGCC
9601	CTGACACCGG	CTTAGGTTCT	TGTAGTAGTC	ATGCATGAGC	CTCTCGATGT	CATCACTGGC
9661	GGAGGCGGAG	TCTTCCATGC	GGGTGACCCC	GACGCCCTTG	AGCGGCTGCA	CGAGCGCCAG
9721	GTCGGCGACG	ACGCGCTCGG	CGAGGATGGC	CTGTTGCACG	CGGGTGAGGG	TGTCCTGGAA
9781	GTCGTCCATG	TCGACGAAGC	GGTGGTAGGC	CCCTGTGTTG	ATGGTGTAAAG	TGCAGTTGGC
9841	CATGAGCGAC	CAGTTGACGG	TCTGCAGGCC	GGGCTGCACG	ACCTCGGAGT	ACCTGAGCCG
9901	CGAGAAGGCG	CGCGAGTCGA	AGACGTAGTC	GTTCGAGGTG	CGCACAAGGT	ACTGGTATCC
9961	GACTAGGAAG	TGCGGCGGGC	GCTGGCGGTA	GAGCGGCCAG	CGCTGGGTGG	CCGGCGCGCC
10021	CGGGGCCAGG	TCCTCGAGCA	TGAGGCGGTG	GTAGCCGTAG	AGGTAGCGGG	ACATCCAGGT
10081	GATGCCGGCA	GCGGTGGTGG	AGGCGCGCGG	GAAGTCCGGG	ACGCGGTTCC	AGATGTTGCG
10141	CAGCGGCAGG	AAATAGTCCA	TGGTGGGCAC	GGTCTGGCCG	GTGAGACCGG	CGCAGTCATT
10201	GACGCTCTAG	AGGCAAAAAC	GAAAGCGGTT	GAGCGGGCTC	TTCTTCCGTA	GCCTGGCGGA

10261 ACGCAAACGG GTTAGGCCGC GCGTGTACCC CGGTTTCAGT CCCCTCGAAT CAGGCTGGAG
10321 CCGCGACTAA CGTGGTATTG GCACTCCCGT CTCGACCCGA GCCCGATAGC CGCCAGGATA
10381 CGCGGGAAGA GCCCTTTTGG CCGGCCGARG GGAGTCGCTA GACTTGAAAG CGGCCGAAAA
10441 CCCC GCCGGG TAGTGGCTCG CGCCCGTAGT CTGGAGAAGC ATCGCCAGGG TTGAGTCGCG
10501 GCAGAACCCG GTTCGCGGAC GGCCGCGGCG AGCGGGACTT GGTCACCCCG CCGATTTAAA
10561 GACCCACAGC CAGCCGACTT CTCCAGTTAC GGGAGCGAGC CCCCTTTTTT CTTTTTGCCA
10621 GATGCATCCC GTCTGCGCC AAATGCGTCC CACCCCCCG GCGACCACCG CGACCGCGGC
10681 CGTAGCAGGC GCCGGCGCTA GCCAGCCACA GCCACAGACA GAGATGGACT TGGAAGAGGG
10741 CGAAGGGCTG GCGAGACTGG GGGCGCCTTC CCCGGAGCGA CACCCCCGCG TGCAGCTGCA
10801 GAAGGACGTG CGCCCGGCGT ACGTGCTGTC GCAAAACCTG TTCAGGGACC GCAGCGGGGA
10861 GGAGCCCAG GAGATGCGCG ACTGCCGGTT TCGGGCGGGC AGGGAGCTGC GCGAGGGCCT
10921 GGACCGCCAG CGCGTGCTGC GCGACGAGGA TTTTCGAGCCG AACGAGCAGA CGGGGATCAG
10981 CCCC GCCGCG GCGCACGTGG CCGCGGCCAA CCTGGTGACG GCCTACGAGC AGACGGTGAA
11041 GCAGGAGCGC AACTTCCAAA AGAGTTTCAA CAACCATGTG CGCACCTGA TCGCCGCGCA
11101 GGAGGTGGCC CTGGGCCTGA TGCACCTGTG GGACCTGGCG GAGGCCATCG TCGAGAACCC
11161 GGACAGCAAG CCTCTGACGG CGCAGCTGTT CTGGTGGA CAGCACAGCA GGGACAACGA
11221 GCGTTTCAGG GAGGCGCTGC TAAACATCGC CGAGCCGAG GGTGCTGGC TGTGGAGCT
11281 GATCAACATC TTGCAGACGA TCGTAGTTCA GGAGCGCAGC CTGAGCTTGG CCTGAGAGGT
11341 GGCGGCAATC AACTACTCGG TCGTTAGCCT GGGCAAGTTT TACGCGCGCA AGATTTACAA
11401 GACGCCGTAC GTGCCCATAG ACAAGGAGGT GAAGATAGAC AGCTTTTACA TGCGCATGGC
11461 GCTCAAGGTG CTGACGCTGA GCGACGACCT GGGCGTGATC CGCAACGACC GCATCCACAA
11521 GGCCGTGAGC GCGAGCCGGC GCGCGAGCT GAGCGACCGC GAGCTGATGC TGAGCCTGCG
11581 CCGGGCGCTG GTAGGGGGCG CCGCCGGCGG CGAGGAGTCY TACTTCGACA TGGGGGCGGA
11641 CCTGCATTGG CAGCCGAGCC GCGCGCCTT GGAGGCCGCC TACGGTCCAG AGGACTTGGA
11701 TGAGGAAGAG GAAGAGGAGG AGGATGCACC CGCTGCGGGG TACTGACGCC TCCGTGATGT
11761 GTTTTTCAGT GCAGCAAGCC CCGGACCCCG CCATAAGGGC GCGCTGCAA AGCCAGCCGT
11821 CCGTCTAGC ATCGGACGAC TGGGAGGCTG CGATGCAACG CATCATGGCC CTGACGACCC
11881 GCAACCCCGA GTCCTTTAGA CAACAGCCGC AGGCCAACAG ACTCTCGGCC ATTCTGGAGG
11941 CCGTGGTCCC TTCTCGGACC AACCACCGC ACGAGAAGGT GCTGGCGATC GTGAACCGCG
12001 TGGCGGAGAA CAAGGCCATC CGTCCCGACG AGGCCGGGCT AGTGATACAA GCCCTGCTGG
12061 AGCGCGTAGG CCGCTACAAC AGCACAACG TGCAGTCCAA CCTGGACCGG CTGGTGACGG
12121 ACGTGGCGCA AGCCGTGGCG CAGCGCGAGC GGTTCAGAA CGAGGGCCTG GGCTCGCTGG
12181 TGGCGCTGAA CGCCTTCCTG GCGACGAGC CGGCGAACGT GCCGCGCGGG CAGGATGATT
12241 ACACCAACTT TATCAGCGCG CTGCGGCTGA TGGTGACCGA GGTGCCCCAG AGCGAGGTGT
12301 ACCAGTCGGG CCGGACTAC TTTTTCAAA CTAGCAGACA GGGCCTGCAA ACGGTGAACC
12361 TGAGCCAGGC TTTCAAGAAC CTGCGCGGGC TGTGGGGCGT GCAGGCGCCC GTGGGCGACC
12421 GGTGACGGT GAGCAGCTTG CTGACGCGCA ACTCGCGGT GCTGCTGCTG CTGATCGCGC
12481 CCTTCACCGA CAGTGGCAGC GTAAACCGCA ACTCGTACCT GGGTCACCTG CTAACGCTGT
12541 ACCGCGAGGC CATAGGCCAG GCGCAGGTGG ACGAGCAGAC CTTCCAGGAG ATCACTAGCG
12601 TGAGCCGCGC GCTGGGGCAG AACGACACCG ACAGTCTGAG GGCCACCCCTG AACTTCTTGC
12661 TGACCAATAG ACAGCAGAAG ATCCCGGCGC AGTACGCGCT GTCGGCCGAG GAGGAGCGCA
12721 TCCTGAGATA TGTGCAGCAG AGCGTAGGGC TTTTCCTGAT GCAGGAGGGG GCCACTCCCA
12781 GCGCCGCGCT GGACATGACC GCGCGCAACA TGGAACCTAG CATGTACGCC GCCAACCGGC
12841 CGTTTATCAA TAAGCTAATG GACTACCTGC ATCGCGCGGC GTCCATGAAC TCGGACTACT
12901 TTACCAATGC CATTTTGAAC CCGCACTGGC TTCCGCGGCC GGGGTTCAT ACGGGCGAGT
12961 ACGACATGCC CGACCCCAAC GACGGGTTTT TGTGGGACGA CGTGGACAGC GCGGTGTTTT
13021 CACCGACCTT GCAAAAGCGC CAGGAGGCGG TCGCGACGCC CGCGAGCGAG GCGCGGTTGG
13081 GTCGGAGCCC CTTTCCTAGC TTAGGGAGTT TGCATAGCTT GCCGGGCTCT GTGAACAGCG
13141 GCAGGGTGAG CCGGCCGCGC TTGCTGGGCG AGGACGAGTA CCTGAACGAC TCGCTGCTGC
13201 AGCCGCCGCG GGTCAAGAAC GCCATGGCCA ATAACGGGAT AGAGAGTCTG GTGGACAAAC
13261 TGAACCGCTG GAAGACCTAC GCTCAGGACC ATAGGAGACC TGCGCCCGCG CCGCGGCGAC
13321 AGCGCCACGA CCGGCAGCGG GGCCTGGTGT GGGACGACGA GGA CTGCGCC GACGATAGCA
13381 GCGTGTGGGA CTTGGGCGGG AGCGGTGGGG TCAACCCGAT ATCGCGCATC CTGCAGCCCA
13441 AACTGGGGCG ACGGATGTTT TGAATGCAAA ATAAACTCA CCAAGGCCAT AGCGTGCGTT
13501 CTCTTCCTTG TTAGAGATGA GCGGTGCGGT GGTGTCTTCC TCTCTCTCCT CCTCGTACGA
13561 GAGCGTGATG GCGCAGGCGA CCCTGGAGGT TCCGTTTGTG CCTCCGCGGT ATATGGCTCC
13621 TACGGAGGGC AGAAACAGCA TTCGTTACTC GGAGCTGGCT CCGTTGTACG ACACCACTCG

13681 CGTGTACTTG GTGGACAACA AGTCGGCGGA CATCGCTTCC CTGAACTATC AAAACGACCA
13741 CAGCAACTTC CTGACCACGG TGGTGCAGAA CAACGATTTC ACCCCGCGG AGGCTAGCAC
13801 GCAGACGATA AATTTTGACG AGCGGTGCGG GTGGGGCGGT GATCTGAAGA CCATTCTGCA
13861 CACCAACATG CCCAATGTGA AAGCACCAC AGGGGGTAGA AGCAACAGAT TTAAGCAAGG ATATCTTAGA
13921 GGTGGCTAGA AAACACCCAC AGGGGGTAGA AGCAACAGAT TTAAGCAAGG ATATCTTAGA
13981 GTATGAGTGG TTTGAGTTTA CCCTGCCCCG GGGCAACTTT TCCGAGACCA TGACCATAGA
14041 CCTGATGAAC AACGCCATCT TGGAAAACTA CTTGCAAGTG GGGCGGCAAA ATGGCGTGCT
14101 GGAGAGCGAT ATTGGAGTCA AGTTTGACAG CAGAAATTTT AAGCTGGGCT GGGACCCGTG
14161 GACCAAGCTG GTGATGCCAG GGGTCTACAC CTACGAGGCC TTTCACCCGG ACGTGGTGCT
14221 GCTGCCGGGC TGGGGGTGG ACTTCACAGA GAGCCGCTG AGCAACCTCC TGGGCATTG
14281 CAAGAAGCAA CCTTTCCAAG AGGGCTTCAG AATCATGTAT GAGGATCTAG AAGGGGGCAA
14341 CATCCCGGCC CTGCTGGATG TGCCCAAGTA CTTGGAAAGC AAGAAGAAGT TAGAGGAGGC
14401 ATTGAGAAT GCTGCTAAAG CTAATGGTCC TGCAAGAGGA GACAGTAGCG TCTCAAGAGA
14461 GGTGAAAAG GCAGCTGAAA AAGAACTTGT TATTGAGCCC ATCAAGCAAG ATGATACCAA
14521 GAGAAGTTAC AACCTCATCG AGGGAACCAT GGACACGCTG TACCGCAGCT GGTACCTGTC
14581 CTATACCTAC CGGGACCCTG AGAACGGGT GCAGTCGTGG ACGCTGCTCA CCACCCCGGA
14641 CGTCACCTGC GCGCGGAGC AAGTCTACTG GTCGCTGCCG GACCTCATGC AAGACCCGT
14701 CACCTTCCGT TCTACCCAGC AAGTCAGCAA CTACCCCGTG GTCGGCGCCG AGCTCATGCC
14761 CTTCCGCGCC AAGAGCTTTT ACAACGACCT CGCCGTCTAC TCCAGCTCA TCCGCAGCTA
14821 CACCTCCCTC ACCCACGTCT TCAACCGCTT CCCCAGAAC CAGATCCTCT GCCGTCCGCC
14881 CGCGCCACC ATCACCACCG TCAGTAAAA CGTGCCTGCT CTCACAGATC ACGGGACGCT
14941 ACCGCTGCGC AGCAGTATCC GCGAGTCCA GCGAGTGACC GTCAGTACG CCCGTGCGCG
15001 CACCTGTCCC TACGTCTACA AGGCCCTGGG CATAGTCGCG CCGCGTGTGC TTTCCAGTCG
15061 CACCTTCTAA AAAATGTCTA TTCTCATCTC GCCAGCAAT AACACCGGT GGGGTATTAC
15121 TAGGCCAGC AGCATGTACG GAGGAGCCAA GAAACGTCCC AGCAGCACC CGTCCGCGTC
15181 CGCGCCACT TCCGCGCTCC GTGGGGCGCT TACAAGCGCG GCGGACTGC CACCGCCGCC
15241 GCCGTGCGCA CCACCGTCGA CGACGTCATC GACTCGGTGG TCGCCGACGC GCGCAACTAT
15301 ACTCCCGCCC CTTGACCGT GGACGCGGT CATTGACAGC GTGGTGGCGA CGCGCGCGCG
15361 ATATGCCAGA CGCAAGAGCC GCGGGCGGA CGGATCGCCC AGGCGCCATT CGGAGCACGC
15421 CCGCATGGG GCGCGCCCG AGCTCTGCTG CGCGCGCCA GACGCACGGG CCGCGGGGCC
15481 ATGATGCGAG CCGCGCGCCG CGCCGCCACT GCACCCCCCG CAGGCAGGAC TCGCAGACGA
15541 GCGCGCGCCG CCGCGCGCCG GGCCATCTCT AGCATGACCA GACCCAGGCG CGGAAACGTG
15601 TACTGGGTGC GCGACTCCGT CACGGGCGTG CGCGTGCCCG TGCGCACCCG TCCTCTCTCGT
15661 CCTGATCTA ATGCTTGTGT CCTCCCCCG AAGCGACGAT GTCAAAGCGC ATCTACAAGA
15721 GAGATGCTCC AGGTGCTCGC CCCGAGATT TACGACCAC CCCAGGCGGA CCAGAAACCC
15781 CGCAAAATCA AGCGGGTTAA AAAAAAGGAT GAGGTGGACG AGGGGGCAGT AGAGTTTGTG
15841 CCGGAGTTG CTCCGCGCGC GCGCGTAAAT TGAAGGGGC GCAGGTGCAC GCGTGTGCG
15901 GCGCGCACG GCGGTGGTGT TCACGCCCCG CGAGCGGTCC TCGGTGAGGA GCAAGCGTAG
15961 CTATGACGAG GTGTACGGC ACGACGACAT CCTGGACCAG GCGGCAGAGC GGGCGGGCGA
16021 GTTTGCCTAC GGAAGCGGT CGCGCAAGA GGAGCTGATC TCGTGCCCG TGGACGAGAG
16081 CAATCCACG CCGAGCCTGA AGCCCGTGAC CTGCAGCAGG TGCTGCCCA GCGGTGCTG
16141 CTGCCGAGCC GCGGGATCAA GCGCGAGGGC GAGAACATGT ACCCGACCAT GCAGATCATG
16201 GTGCCAAAGC GCGGGCGCGT GGAGGAAGTG CTGGACACCG TGAAAATGGA TGTGGAGCCC
16261 GAGGTCAAGG TGCGCCCCAT CAAGCAGGTG GCGCGGGGCC TGGCGTGCA GACCGTGGAC
16321 ATTCAGATCC CCACCGACAT GGATGTCGAG AAAAAACCT CGACCAGCAT CGAGGTGCAG
16381 ACCGACCCCT GGCTCCCGT CTCCACCGCT ACCGCTTCCA CTTCTACCGT CGCCACGGTC
16441 ACCGAGCCCT CCAGGAGGCG AAGATGGGGC CCGCCAACC GGCTGATGCC CAACTACGTG
16501 TTGCATCCTT CCATTATCCC GACGCGGGC TACCGCGCA CCCGTTACTA CGCCAGCCGC
16561 AGGCGCCCAG CCAGCAAACG CCGCGCCGC ACCGCCACC GCGCGCTCT GCGCCCGCC
16621 CCGTGCGCC GCGTAACCAA CCGCGCGGG CCGCTCGCTC GTTCTGCCA CCGTGCGCTA
16681 CCACCCAGC ATCCTTTAAT CCGTGTGCTG TGATACTGTT GCAGAGAGAT GGCTCTCACT
16741 TGCCGCTGC GCATCCCGT TCCGAATTAC CGAGGAAGAT CCCCGCGCAG GAGAGGCATG
16801 GCAGGCAGC GCCTGAACCG CCGCGGGCG GGGCCATGC GCAGGCGCT GAGTGGCGGC
16861 TTTCTGCCG CGCTCATCCC CATAATCGCG GCGCCATCG GCACGATCCC GGGCATAGCT
16921 TCCGTTGCGC TGCAGGCGTC GCAGCGCGT TGATGTGCGA ATAAAGCCTC TTTAGACTCT
16981 GACACACCTG GTCCTGTATA TTTTGTAGAT GGAAGACATC AATTTTGCCT CCCTGGCTCC
17041 GCGGCACGGC ACGCGCCGT TCATGGGCAC CTGGAACGAG ATCGGCACCA GCCAGCTGAA

17101 CGGGGGCGCC TTCAATTGGA GCAGTGTCTG GAGCGGGCTT AAAAATTTTCG GCTCGACGCT
 17161 CCGGACCTAT GGGAAACAAGG CCTGGAATAG TAGCACGGGG CAGTTGTTGA GGGAAAAGCT
 17221 CAAAGACCAG AACTTCCAGC AGAAGGTGGT GGACGGCCTG GCCTCGGGCA TTAACGGGGT
 17281 GGTGGACATC GCGAACCAGG CAGTGCAGCG CGAGATAAAC AGCCGTCTGG ACCCGCGGCC
 17341 GCCCACGGTG GTGGAGATGG AAGATGCAAC TCTTCCGCCG CCGAAGGGCG AGAAGCGGCC
 17401 GCGGCCAGAT GCGGAGGAGA CGATCCTGCA GGTGGACGAG CCGCCTTCGT ACGAGGAGGC
 17461 CGTGAAGGCC GGCATGCCCA CCACGCGCAT CATCGCGCCA CTGGCCACGG GTGTAATGAA
 17521 ACCCGCCACC CTTGACCTGC CTCCACCACC CACGCCCCTG CCACCGAAGG CAGCTCCGGT
 17581 TGTGCAGCCC CCTCCGGTGG CGACCGCCGT GCGCCGCGTC CCCGCCCGCC GCCAGGCCCA
 17641 GAACTGGCAG AGCACGCTGC ACAGTATTGT GGGCCTGGGA GTGAAAAGTC TGAAGCGCCG
 17701 CCGATGCTAT TGAGAGAGAG GAAGGAGGAC ACTAAAGGGA GAGCTTAACT TGTATGTGCC
 17761 TTACCGCCAG AGAACGCGCG AAGATGGCCA CCCCCTCGAT GATGCCGCAG TGGGCGTACA
 17821 TGCACATCGC CGGCGAGGAC GCCTCGGAGT ACCTGAGCCC GGGTCTGGTG CAGTTTGCCC
 17881 GCGCCACCGA CACGTACTTC AGCCTGGGCA ACAAGTTTAG GAACCCACG GTGGCCCCGA
 17941 CCCACGATGT GACCACGGAC CCGTCCCAGC GTCTGACGCT GCGCTTTGTG CCCGTGGATC
 18001 GCGAGGACAC CAGTACTCGT ACAAGGCGCG CTTCACTCTG GCCGTGGGCG ACAACCGGGT
 18061 GCTAGACATG GCCAGCACGT ACTTTGACAT CCGCGGCGTC CTGGACCGCG GTCCCACTTT
 18121 CAAACCTTAC TCGGGCACGG CTTACAACAG CCTTGCCCCC AAGGGCGCTC CCAATCCAG
 18181 TCAGTGGGTT GCCAAAGAAA ATGGTCAGGG AACTGATAAG ACACATACTT ATGGCTCAGC
 18241 TGCCATGGGA GGAAGCAACA TCACCATGTA AGGTTTAGTA ATTGGAAGTG ATGAAAAAGC
 18301 TGAGGATGGC AAAAAAGATA TTTTTCGAAA TAACTTTAT CAGCCAGAAC CTCAGTAGG
 18361 TGAAGAAAAC TGGCAAGAGT CTGAAGCCTT CTATGGAGGC AGAGCTCTTA AGAAAGACAC
 18421 AAAAAATGAAG CCCTGCTATG GCTCATTTGC AAGACCTACC AATGAAAAAG GCGGACAAGC
 18481 TAAATTTAAG CCAGTGAAG AGGGGAGCA ACCTAAAGAT TATGACATAG ATTTGGCTTT
 18541 CTTTGACACA CCTGGAGGCA CCATCACAGG AGGCACAGAC GAAGAATATA AAGCAGACAT
 18601 TGTGTTGTAC ACTGAAAATG TCAACCTTGA AACCACAGAC ACCCACGTGG TATACAAGCC
 18661 AGGAAAAGAG GATGACAGTT CAGAAGTAAA TTTGACACAG CAGTCCATGC CCAACAGGCC
 18721 TAACTACATT GGCTTCAGAG ACAACTTTGT GGGACTCATG TACTACAACA GTACTGGCAA
 18781 CATGGGTGTG CTGGCTGGTC AGGCCTCTCA ATTGAATGCT GTGGTCGACT TGCAAGACAG
 18841 AAACACCGAG CTGTCTTACC AGCTCTTGCT AGATTCTCTG GGTGACAGAA CCAGATACTT
 18901 CAGCATGTGG AACTCTGCGG TGGATAGCTA TGATCCAGAT GTCAGGATCA TTGAAAATCA
 18961 TGGTGTGGAA GATGAACTTC CAACTATTG CTTCCCATTG AATGGCACTG GCACCAATTC
 19021 AACATATCTT GCGGTAAAGG TGAAACCAGA TCAAGATGGT GATGTTGAAA GCGAGTGGGA
 19081 TAAAGATGAT ACCATTGCAA GGCAGAATCA AATCGCCAAG GGCAACGTCT TTGCCATGGA
 19141 GATCAACCTC CAGGCCAACC TGTGGAAGAG TTTTCTGTAC TCGAACGTGG CCTTGTACCT
 19201 GCCCGACTCC TACAAGTACA CGCCGCCCAA TGTACGCTG CCCGCCACA CCAACACCTA
 19261 CGAGTACATG AACGGCCGCG TGGTAGCCCC CTCGCTGGTG GACGCCTACA TCAACATAGG
 19321 CGCCCGATGG TCGCTGGACC CCATGGACAA CGTCAACCCC TTCAACCACC ACCGCAATGC
 19381 GGGCCTGCGC TACCGCTCCA TGCTTCTGGG CAACGGCCGC TACGTGCCCT TCCACATCCA
 19441 AGTGCCCCAA AAGTTCTTTG CCATCAAGAA CTGCTCCTG CTCCCGGGCT CCTACACCTA
 19501 CGAGTGGAAC TTCCGCAAGG ATGTCAACAT GATCCTGCAG AGTTCCCTCG GCAACGACCT
 19561 GCGCGTCGAC GGCGCTCCG TCCGCTTCGA CAGCGTCAAC CTCTACGCCA CCTTCTTCCC
 19621 CATGGCGCAC AACACCGCCT CCACCTGGA AGCCATGCTG CGCAACGACA CCAACGACCA
 19681 GTCCTTCAAC GACTACCTCT CGGCCGCCAA CATGCTCTAC CCCATCCCGG CCAAGGCCAC
 19741 CAACGTGCCC ATCTCCATCC CCTCGCGCAA CTGGGCGGCT TTTCGCGGCT GGAGTTTCAC
 19801 CCGTCTGAAA ACCAAGGAAA CTCCCTCCCT CGGCTCGGGT TTTGACCCCT ACTTTGTCTA
 19861 CTCGGGCTCG ATCCCTTACC TTGACGGACC CTTTACCTT AACCACACCT TCAAGAAAGT
 19921 CTCCATCATG TTCGACTCCT CGGTCAGCTG GCGCGCAAC GACCGGCTGC TCACGCCGAA
 19981 CGAGTTGAG ATCAAGCGCA GCGTCGACGG GGAAGGCTAC AACGTGGCCC AATGCAACAT
 20041 GACCAAGGAC TGGTTCCTCG TCCAGATGCT CTCCCACTAC AACATCGGCT ACCAGGGCTT
 20101 CCACGTGCCC GAGGGCTACA AGGACCGCAT GTACTCCTTC TTCCGCACT TCCAGCCCAT
 20161 GAGCAGGAG GTGGTCGATG AGATCAACTA CAAGGACTAC AAGGCCGTCA CCCTGCCCTT
 20221 CCAGCACAAAC AACTCGGGCT TCACCGGCTA CCTTGACCCC ACCATGCGCC AAGGGCAGCC
 20281 CTACCCCGCC AACTTCCCTT ACCCGCTCAT CGGCCAGACA GCCGTGCCAT CCGTCACCCA
 20341 GAAAAGTCTC CTCTGCGACA GGGTCATGTG GCGCATCCCC TTCTCCAGCA ACTTCATGTC
 20401 CATGGGCGCC TTCACCGACC TGGGTGAGAA CATGTTCTAC GCCAACTCG CCCACGCGCT
 20461 CGACATGACC TTCGAGGTGG ACCCATGGA TGAGCCACC GTCCTCTATC TTCTCTTCGA

20521 AGTGTTCGAC GTGGTCAGAG TGCACCAGCC GCACCGCGGC GTCATCGAGG CCGTCTACCT
 20581 GCGCACGCCG TTCTCCGCCG GAAACGCCAC CACCTAAGCA TGAGCGGCTC CAGCGAAAGA
 20641 GAGCTCGCGT CCATCGTGCG CGACCTGGGC TGCGGGCCTA CTTTTTGGGC ACCCAGACA
 20701 CAGCGATTCC CGGGCTTTCT TGCCGGCGAC AAGCTGGCCT GCGCCATTGT CAACACGGCC
 20761 GGCCGCGAGA CCGGAGGCGT GCACTGGCTC GCCTTCGGCT GGAACCCGCG CTCGCGCACC
 20821 TGCTACATGT TCGACCCCTT TGGGTTCCTG GACCGCCGGC TCAAGCAGAT TTACAGCTTC
 20881 GAGTACGAGG CCATGCTGCG CCGAAGCGCC GTGGCCTCTT CGCCCGACCG CTGTCTCAGC
 20941 CTCGAACAGT CCACCCAGAC CGTGCAGGGG CCCGACTCCG CCGCCTGCGG ACTTTTCTGT
 21001 TGCATGTTCT TGATGCTCTT CGTGCCTGG CCCGACCGAC CCATGGACGG GAACCCACC
 21061 ATGAACTTGC TGACGGGGGT GCCCAACGGC ATGCTACAAT CGCCACAGGT GCTGCCCACC
 21121 CTCAGGCGCA ACCAGGAGGA GCTCTATCGC TTCTTCGCGC GCCACTCCCC TTACTTTTCGC
 21181 TCCCACCGCG CCGCCATCGA ACACGCCACC GCTTTTGACA AAATGAAACA ACTGCGTGTA
 21241 TCTCAATAAA CAGCACTTTT ATTTTACATG CACTGGAGTA TATGCAAGTT ATTTAAAGT
 21301 CGAAGGGGTT CTCGCGCTCA TCGTTGTGCG CCGCGCTGGG GAGGGCCACG TTGCGGTACT
 21361 GGTACTTGGG CTGCCACTTG AACTCGGGGA TCACCAGTTT GGGCACTGGG GTCTCGGGGA
 21421 AGGTCTCGCT CCACATACGC CGGCTCATCT GCAGGGCGCC CAGCATGTCC GGGGCGGATA
 21481 TCTTGAAATC GCAGTTGGGA CCGGTGCTCT CCGCGCGCGA GTTGCCTGAC ACGGGGTTGC
 21541 AGCACTGGAA CACCATCAGA CTGGGGTACT TTACGCTGGC CAGCACGCTC TTGTCTGCTGA
 21601 TCTGATCCTT GTCCAGATCC TCGGCGTTGC TCACGCCGAA TGGGGTCATC TTGCACAGTT
 21661 GGCGACCCAG GAATGGCAGC CTCTGAGGCT TGTGGTTACA CTCGCAGTGC ACGGGCATCA
 21721 GCATCATCCC CGCGCCGCGC TGCATATTCG GGTAGAGGCC TTGACAAAGG CCGTGATCTG
 21781 CTTGAAAGCT TGTGCGGCTT TGGCCCCCTC GCTGAAAAAC AGGCCGACG TCTTCCCGCT
 21841 GAACCTGGTA TTCCCGCACC CGGCACCTTG CACGCAGCAG CGCGCGTCAT GGTGCTCAG
 21901 TTGCACACG CTCTTTCCCC AGCGGTTCTG GGTACCTTG GCTTTGCTGG GTTGCTCCTT
 21961 CAACGCGCGC TGCCCGTTCT CGCTGGTCAC ATCCATCTCC ACCACGTGGT CCTTGTGGAT
 22021 CATCACCGTT CCATGCAGAC ACTTGAGCTG GCCTTCCACC TCGGTGCAGC CGTGATCCCA
 22081 CAGGGCACTG CCGGTGCACT CCCAGTTCTT GTGCGCGATC CCGCTGTGGC TGAAGATGTA
 22141 ACCTTGCAAG AGGCGACCCA TGATGGTGCT AAAGCTCTTC TGGGTGGTGA AGGTTAGTTG
 22201 CAGACCGCGG GCCTCCTCGT TCATCCAGGT CTGGCACATC TTTTGGAAGA TCTCGGTCTG
 22261 CTCGGGCATG AGCTTGTAAG CATCGCGCAG GCCGCTGTGC ACGCGGTAAC GTTCCATCAG
 22321 CACGTTTCATG GTATCCATGC CTTTTTCCCA GGACGAGACC AGAGGCAGAC TCAGGGGGTT
 22381 GCGCACGTTT AGGACACCGG GGGTCKCGGG CTCGACGATA CGTTTTCCGT CCTTGCCTTC
 22441 CTTCAACAGA ACCGGAGGCT GGCTGAATCC CACTCCCACA ATCACGGCAT CTTCTGCGG
 22501 CATCTCTTCG TCGGGGTCTA CTTGGTGCAC ATGCTTGGTC TTTCTGGCTT GCTTCTTTTT
 22561 TGGAGGGCTG TCCACGGGGA CCACGTCTTC TCGGAAGACC CGGAGCCAC CCGCTGATAC
 22621 TTTCCGCGCT TGGTGGGCAG AGGAGGTGGC GGCGGCGAGG GGCTCCTCTC GTGCTCCGGC
 22681 GGATAGCGCG CCGACCCGTG GCCCGGGGCG GGAGTGGCCT CTCGCTCCAT GAACCGCGC
 22741 ACCTCTGACT GCCGCGGCGC ATTGTTTCCT AGGGGAAGAT GGAGGAGCAG CCGGTAAGC
 22801 AGGAGCAGGA GAGGACTTA ACCACCACCG AGCAACCCAA AATCGAGCAG CACCTGGGCT
 22861 TCGAAGAGCC GGCTCGTCTA GAACCCACA GGATGAACAG GAGCACGAGC AAGACGAGG
 22921 CCAGGAGGAG ACCGACGCTG GGCTCGAGCA TGGCTACCTG GGAGGAGAGG AGGATGTGCT
 22981 GCTGAAACAC CTGCAGCGCC AGTCCCTCAT CCTCCGGGAC GCCCTGGCCG ACCGAGCGA
 23041 AACCCCCCTC AGCGTCGAGG AGCTGTGTCG GGCTACGAG CTCAACCTCT TCTCGCCGCG
 23101 CGTGCCCCC AAACGCCAGC CCAACGGCAC CTGCGAGCCC AACCCGCGTC TCAACTTCTA
 23161 TCCCGTCTTT GCGGTCCCCG AGGCCCTTGC CACCTATCAC ATCTTTTCA AGAACCAAAA
 23221 GATCCCCGTC TCCTGCCGCG CCAACCGCAC CCGCGCCGAC GCGCTCCTCG CTCTGGGGCC
 23281 CGGCGCGCGC ATACCTGATA TTGCTTCCCT GGAAGAGTGC CAAAATCTT CGAAGGGCTC
 23341 GGTCCGGACG AGACGCGCGC GGCGAAACGC TCTGAAAGAA ACAGCAGAGG AAGAGGGTCA
 23401 CACTAGCGCC CTGGTAGAGT TGGAAGGCGA CAACGCCAGG CTGGCCGTGC TCAAGCGCAG
 23461 CGTTGAGCTC ACCCACTTCG CTAACCCCGC CGTCAACCTC CCGCCCAAGG TCATGCGTGC
 23521 CATCATGGAT CAGCTAATCA TGCCCCACAT CGAGGCCCTC GATGAAAGTC AGGAGCAGCG
 23581 CCCCAGGAGC ACCCGGCCCG TGGTCAGCGA TGAGCAGCTT GCGCGCTGGC TTGGTACCCG
 23641 CGACCCCAAG GCCCTGGAGC AGCGGCGCAA GCTCATGCTG GCCGTGGTCC TGGTCACCTT
 23701 CGAGTTCGAA TGATGCTGAC GCTTTTTCAG GACCCCGAG ACCTGCGCAA GGTGAGGAG
 23761 ACCTGCACTA CACTTTTTCG ACCTTTTCGTC AGGCAGGCAT GCAAGATCTC CAACGTGGAG
 23821 CTGACCAACT GGTCTCCTGC CTGGGAATCC TGCACGAGAA CCGCCTGGGG CAGACAGTGC
 23881 TCCACTCGAC CCTGAAGGGC GAGGCGCGGC GGGACTATGT CCGCGACTGC GTCTTCTCT

23941 TTCTCTGCCA CACATGGCAA GCTGCCATGG GCGTGTGGCA GCAGTGTCTC GAGGACGAGA
24001 ACCTGAAGGA GCTGGACAAG CTTCTTGCTA GAAACCTCAA AAAGCTGTGG ACGGGCTTTG
24061 ACGAGCGCAC CGTCGCCCTCG GACCTGGCCG AGATCGTCCT CCCCCGAGCG CCTGAGGCAG
24121 ACGCTGAAAAG GCGGGCTGCC CGACTTCATG AGCCAGAGCA TGTTGCAAAA CTACCGCACT
24181 TTCAATTCTCG AGCGATCTGG GATGCTGCCC GCCACCTGCA ACGCCTTCCC CTCCGACTTT
24241 GTCCCGCTGA GCTACCGCGA GTGTCCCCCG CCGCTGTGGA GCCACTGCTA CCTCTTGCAG
24301 CTGGCCAACT ACATCGCCTA CCACTCGGAT GTTATCGAGG ACGTGAGCGG CGAGGGGCTG
24361 CTAGAGTGCC ACTGCCGCTG CAACCTGTGC TCTCCGCACC GCTCCTGGTC TGCAACCCCC
24421 AGTCCTGAG CGAGACCCAG GTCATCGGTA CCTTCGAGCT GCAAGGTCCG CAGGAGTCCA
24481 CCGCTCCGCT GAAACTCACG CCGGGGTTGT GGACTTCCGC GTACCTGCGC AAATTTGTAC
24541 CCGAGGACTA CCACGCCCAT GAGATAAAGT TCTTCGAGGA CCAATCGCGC CCGCAGCACG
24601 CGGATCTCAC GGCTTCCGTC ATCACCAGG GCGCGATCCT CGCCCAATTG CACGCCATCC
24661 AAAAATCCCG CCAAGAGTTT CTTTTGAAAA AGGGTAGAGG GGTCTATCTG GACCCCCAGA
24721 CGGGCGAAGT GCTCAACCCG GGTCTCCCCC AGCATGCCGA AGAAGAACAG GAGCCGCTAG
24781 TGGAAGAGAT GGAAGAAGAA TGGGACAGCC AGCAGAAGAA GACGAATGGG AAGAAGAGAC
24841 AGAAGAAGAA GAATTGGAAA AGTGGAAGAA GAGCAGCACA GACACCGTCG CCGCACCATC
24901 CGCGCCGCGAG CCCGGCGGTC ACGGATACAA CTCGCAGTCC GCCAAGCTCC TCGTAGATGG
24961 ATCGAGTGAA GGTGACGGTA AGCACGAGCG GCAGGGCTAC GAATCATGGA GGCCCACAAA
25021 GCGGGATCAT CGCCTGCTTG CAAGACTGCG GGGGGAACAT CGTTTCGCCC GCCGCTATCT
25081 GCTCTTCCAT CGCGGGTGTA ACATCCCCCG CAACGTGTTG CATTACTACC GTCACCTTCA
25141 CAGCTAAGAA AAAATCAGAG TAAGAGGAGT CGCCGGAGGA GGCNTGAGGA TCGCGGCGAA
25201 CGAGCCATTG ACCACCAGGG AGCTGAGGAA TCGGATCTTC CCCACTCTTT ATGCGATTTT
25261 TCAGCAGAGT CGAGGTCAGC AGCAAGAGCT CAAAGTAAAA AACC GGTCCTC
25321 CACCCGCAGT TGCTTGTAAC ACAAAAACGA AGATCAGCTG CAGCGCACTC TCGAAGACGC
25381 CGAGGCTCTG TTCCACAAGT ACTGCGCGCT CACTCTTAAA GACTAAGGCG CGCCCACCCG
25441 GAAAAAAGGC GGGAAATTACC TCATCGCCAC CATGAGCAAG GAGATTCCCA CCCCTTACAT
25501 GTGGAGCTAT CAGCCCCAGA TGGGCCGTCG CGCGGGCGCC TCCCAGGACT ACTCCACCCG
25561 CATGAACTGG CTCAGTGCCG GCCCCTCGAT GATCTCACGG GTCAACGGGG TCCGTAACCA
25621 TCGAAACCAG ATATTGTTGG AGCAGGCGGC GGTCACTCA ACGCCCAGGC AAAGCTCAAC
25681 CCGCGTAATT GGCCCTCCAC CCTGGTGTAT CAGGAAATCC CCGGGCCGAC TACCGTACTA
25741 CTTCCGCGTG ACGCACTGGC CGAAGTCCCG ATGACTAACT CAGGTGTCCA GCTGGCCGGC
25801 GGCGCTTCCC GGTGCCCCGT CCGCCCACAA TCGGGTATAA AAACCTGGT GATACGAGGC
25861 AGAGGCACAC AGCTCAACGA CGAGTTGGTG AGCTCTTCAA TCGGTCTGCG ACCGGACGGA
25921 GTGTTCCAAC TAGCCGAGC CGGGAGATCG TCCTTCACTC CCAACCAGGC TACCTGACCT
25981 TGCAGAGCAG CTCTTCGGAG CCTCGCTCCG GAGGCATCGG AACCTCCAG TTGTGGAGG
26041 AGTTTGTGCC CTCGGTCTAC TTCAACCCCT TCTCGGGATC GCCAGGCCTC TACCCGGACG
26101 AGTTTGTGCC GAACTTCGAC GCAGTGAGAG AAGCGGTGGA CGGCCACGAC TGAATGTCTT
26161 ATGGTGAGTC GCTGAGCTC GCTCGGTTGA GGCACCTAGA CCACTGCGCG CGCTGCGCT*
26221 GCTTCGCCCC GGAGAGCTGC GGACTTATCT ACTTTGAGTT TCCCAGGAG CACCCACCT
26281 GCCCTGCACA CGGAGTGCGG ATCACCCTAG AGGGCACCAC CGAGTCTCAC CTGGTTAGGT
26341 TCTTCAACCA GCAACCTTC CTGGTCGAGC GGGACCGGGG AGGCACCACC TACCCGTCT
26401 ACTGCATCTG TCCAACCCCG AAGTTGCATG AGAATTTTGT TTGTACTCTG TGTGCTGAGT
26461 TTAATAAAAG CTAAACTCCT ACAATACTCT GGGATCCCGT GTCGTGCGAC TCGCAACAAG
26521 ACCTTCAACC TCACCAACCA GACTGAGGTA AAATTCAACT GCAGACCGGG GGACAAATAC
26581 ATCCTCTGGC TTTTAAAAA CACTTCTTTC GCAGTCTCCA ACGCCTGCGC CAACGACGGT
26641 ATTGAAATAC CCAACAACCT TACCAGTGGA CTAACCTATA CTACCAGAAA GACTAAGCTA
26701 GTACTCTACA ATCCTTTTGT AGAGGGAACC TACCCTGCC AGAGCGGACC TTGCTTCCAC
26761 ACTTTCACCT TGGTGAACGT TACCAGACAGC AGCAGAGCCG CTACAGAAAC ATCTAACCTT
26821 CTTTTTGATA CTAACACTCC TAAACCCGGA GGTGAGCTCT GGGTTCCCTC TCTAACAGAG
26881 GGGGGTAAAC ATATTGAAGC GGTGGGTAT TTGATTTTAG GGGTGGTCCT GGGTGGGTGC
26941 ATAGCGGTGC TGTATTACCT TCCTTGCTGG ATCGAAATCA AAATCTTTAT CTGCTGGGTC
27001 AGACAGGTTT GGGAGGAACC ATGAAGGGGC TCTTGCTGAT TATCCTTTCC CTGGTGGGGG
27061 GTGTACTGTC ATGCCACGAA CAGCCACGAT GTAACATCAC CACAGGCAAT GAGAGGAGTG
27121 TGATATGCAC AGTAGTCATC AAATGCGAGC ATACATGCCC TCTCAACATC ACATTCAAAA
27181 ACCGTACCAT GGGAAATGCA TGGGTGGGCG ACTGGGAACC AGGAGATGAG CAGAACTACA
27241 CGGTCACTGT CCATGGTAGC AATGGAAATC ACACCTTTTG TTTCAAATTC ATTTTGAAG
27301 TCATGTGTGA TATCACACTG CATGTGGCTA GACTTCATGG CTTGTGGCCC CCTACCAAGG

27361 ATAACATGGT TGGGTTTTCT TTGGCTTTTG TGATCATGGC CTGTGCAATG TCAGGTCTGC
 27421 TGGTAGGGGC TTTAGTGTGG TTCCTAAAGC GCAAGCCTAG GTATGGAAAT GAGGAGAAGG
 27481 AAAAATTGCT ATAAATCTTT TCTCTTCGCA GAACCATGAA TACAGTGATC CGTATCGTGC
 27541 TGCTCTCTCT TCTTGTAAGT TTTAGTCAGG CAGGATTCAT ACCATCAATG CTACATGGTG
 27601 GGCTAATATA ACTTTAGTGG GACCTCAGAT ATTCCAGATC ACATGGTATG ATAGCACTGG
 27661 ATTGCAATTT TGTGATGGAA GTACAGTTAA GAATCCACAG ATCAGACATA GTTGTAATGA
 27721 TCAAAACTTA ACTCTGATTC ATGTGAACAA AACCCTATGAA AGAACATACA TGGGCTATAA
 27781 TAAGCAGAGT ACTCATAAAG AAGACTATAA AGTCACAGTT ATACCACCTC CTCCTGTTAC
 27841 TGTAAAGCCA CAACCAGAGC CAGAATATGT GTATGTTAAT ATGGGAGAGA ACAAACCTT
 27901 AGTTGGGCCT CCAGGAATTC CAGTTAGTTG GTTTAATCAG GATGGTTTAC AATTTTGCAT
 27961 TGGGGATAAA GTTTTTCATC CAGAATTCAA CCACACCTGT GACATGCAA ATCTTACACT
 28021 GTTGTTTTATA AATCTTACAC ATGATGGAGC TTATCTTGGT TATAATCGCC AGGGAACCTGA
 28081 AAGAACTTGG TATGAGGTTG TAGTGTGAGA TGGTTTTCCA AAATCAGAAG AGATGAAGGT
 28141 AGAAGACCAT AGTAAAGAAA CAGAACAAAA ACAGACTGGT CAAAAACAAA GTGACCATAA
 28201 GCAGGGTGGG CAAAAAGAAA CAAGTCAAAA GAAACTAAT GACAAACAAA AGCCATCGCG
 28261 CAGGAGGCCA TCTAACTAA AGCCAAACAC ACCTGACACA AAATAATTA CAGTCACTAG
 28321 TGGGTCAAAC GTAACCTTAG TTGGTCCAGA TGGAAAGGTC ACTTGGTATG ATGATGATTT
 28381 AAAAAGACCA TGTGAGCCTG GGTATAAGTT AGGGTGTAAG TGTGACAATC AAAACCTAAC
 28441 CCTAATCAAT GTAACATAAC TTTATAGGG AGTTTACTAT GGTACTAATG ACAGAGGCCA
 28501 CAGCAAAAGA TACAGAGTAA AAGTAAACAC TACTAATTCT CAAAGTGTGA AAATTCAGCC
 28561 GTACACCAGG CCTACTACTC CTGATCAGAA ACACAGATTT GAATTGCAAA TTGATTTCTAA
 28621 TCAAGACAAA ATTCCATCAA CTACTGTGGC AATCGTGGTG GGAGTGATCG CGGGCTTTGT
 28681 AACTCTAATC ATTATTTTCA TATGCTACAT CTGCTGCCGC AAGCGTCCCA GGTACATACAA
 28741 TCATATGGTA GACCCACTAC TCAGCTTCTC TTAAGTAAAC TCAGTCACTC TCATTTCAGA
 28801 ACCATGAAGG CTTTCACAGC TTGCGTTCTG ATTAGCATAG TCACACTTAG TTCAGCTGCA
 28861 ATGATTAAATG TTAATGTCAC TAGAGGTGGT AAAATTACAT TGAATGGGAC TTATCCACAA
 28921 ACTACATGGA CAAGATATCA TAAAGATGGA TGGAAAAATA TTTGTGAATG GAATGTTACT
 28981 GCATACAAAT GCTTCAATAA TGGAAAGCATT ACTATTACTG CCACTGCCAA CATTACTTCT
 29041 GGCACATACA AAGCTGAAAG CTATAAAAAT GAAATTAAAA AATTAACCTA TAAAAACAAC
 29101 AAAACCACAT TTGAAGATTC TGGAAATTAT GAGCATCAAA AATTATCTTT TTATATGTTG
 29161 ACAATAATTG AACTGCCTAC AACCAAGGCA CCCACCACAG TTAGTACAAC TACACAGTCA
 29221 ACTGTTAAGA CCACTACTCA CACTACACAG CTAGACACCA CAGTGACAGG TAATCTGTG
 29281 TTGGTTAGGT ATTTGTTGAG GGAGGAAAGT ACTACTGAAC AGACAGAGGC TACCTCAAGT
 29341 GCCTTTATCA GCACTGCAAA TTAACTTCG CTTGCTTGGA CTAATGAAAC CGGAGTATCA
 29401 TTGATGCATG GCCAGCCTTA CTCAGGTTTG GATATTCAAA TTAATTTTCT GGTGTCTGT
 29461 GGGATCTTTA TTCTTGTGGT TCTTCTGTAC TTTGTCTGCT GTAAAGCCAG AAAGAAATCT
 29521 AGGAGGCCCA TCTACAGGCC AGTGATTGGG GAACCTCAGC CACTCCAAGT GGATGGAGGC
 29581 TTAAGGAATC TTCTTTTCTC TTTTACAGTA TGGTGATCAG CCATGATTCC TAGTCTTCC
 29641 TATTTAATAT CCTCTTCTGT CTCTTCAACA TCTGTGCTGC CTTTGCAGCA GTTTCGCACG
 29701 CCTCGCCCGA CTGTCTAGGG CCTTTCCCA CTTACTCTC TTTGCCCTGC TCACCTGCAC
 29761 CTGCGTCTGC AGCATTTGCT GCCTGGTCAT CACCTTCTCT CAGCTCATCG ACTGGTGCTG
 29821 CGCGCGCTAC AATTACTTCA TCATAGTCCC GAATACAGGG ACGAGAAGCT AGCCAGAATT
 29881 TTAAGGCTCA TATGACCATG CAGACTCTGC TCATACTGCT ATCGCTCTTA TCCCATGCCC
 29941 TCGCTACTGC TGATTACTCT AAATGCAAAAT TGGCGGACAT ATGGAATTTT TTAGACTGCT
 30001 ATCAGGAGAA AATTGATATG CCTCCTATT ACTTGGTGAT TGTGGGAATA GTTATGGTCT
 30061 GCTCCTGCAC TTTCTTTGCC ATCATGATCT ACCCTGTGTT TGATCTTGGA TGGAACTCTG
 30121 TTGAGGCATT CACATACACA CTAGAAAGCA GTTCACTAGC CTCCACGCCA CCACCCACAC
 30181 CGCCTCCCCG CAGAAATCAG TTTCCCATGA TTCAGTACTT AGAAGAGCCC CCTCCCCGAC
 30241 CCCCTTCCAC TGTTAGCTAC TTTACATAA CCGGCGGCGA TGACTGACCA CCACCTGGAC
 30301 CTCGAGATGG ACGGCCAGGC CTCCGAGCAG CGCATCCTGC AACTGCGCGT CCGTCAGCAG
 30361 CAGGAGCGTG CCGCCAAGGA GCTCCTCGAT GCCATCAACA TCCACCAGTG CAAGAAGGGC
 30421 ATCTTCTGCC TGGTCAAACA GGCAAAGATC ACCTACGAGC TCGTGTCCAA CGGCAAACAG
 30481 CATCGCCTCA CCTATGAGAT GCCCCAGCAG AAGCAGAAGT TCACCTGCAT GGTGGGCGTC
 30541 AACCCCATAG TCATACCCA GCAGTCGGGC GAGACCAACG GCTGCATCCA CTGCTCCTGC
 30601 GAAAGCCCCG AGTGTATCTA CTCCCTTCTC AAGACCCTTT GCGGACTCCG CGACCTCCTC
 30661 CCCATGAAGT GATGTTGATT AAAAACCAAA AAAAACAATC AGCCCCCTCC CCTATCCCAA
 30721 ATTACTCGCA AAAATAAATC ATTGGAACAT ATCATTTAAT AAAGATCACT TACTTGAAT

30781 CTGAAAGTAT GTCTCTGGTG TAGTTGTTCA GCAGCACCTC GGTACCCTCC TCCCAACTCT
 30841 GGTACTCCAG TCTCCGGCGG GCGGCGAACT TTCTCCACAC CTTGAAAGGG ATGTCAAATT
 30901 CCTGGTCCAC AATTTTCATT GTCTTCCCTC TCAGATGTCA AAGAGGCTCC GGGTGGGAAGA
 30961 TGACTTCAAC CCCGTCTACC CCTATGGCTA CGCGCGGAAT CAGAATATCC CCTTCTCAC
 31021 TCCCCCTTT GTCTCCTCCG ATGGATTCAA AAACCTCCCC CCTGGGGTCC TGTCACCTCAA
 31081 ACTGGCTGAC CCAATCACCA TAGCCAATGG TGATGTCTCA CTCAAGGTGG GAGGGGACTT
 31141 ACTTTGCAAG AAGGAAGTAT GACTGTAGAC CCTAAGGCTC CCTTGCAACT TGCAAACAAT
 31201 AAAAACTTG AGCTTGTTTA TGTTGATCCA TTTGAGGTTA GTGCCAATAA ACTTAGTTTA
 31261 AAAGTAGGAC ATGGATTAAA AATATTAGAT GACAAAAGTG CTGGAGGGTT GAAAGATTTA
 31321 ATTGGCAAAC TTGTGGTTT AACAGGGGAA AGGAATAGGC ACTGAAAATT TGCAAAAATAC
 31381 AGATGGTAGC AGCAGAGGAA TTGGTATAAG TGTAAGAGCA AGAGAAGGGT TAACATTTGA
 31441 CAATGATGGA TACTTGGTAG CATGGAACCC AAAGTATGAC ACGCGCACAC TTTGGACAAC
 31501 ACCAGACACA TCTCCTAATT GCAGGATTGA TAAGGAGAAG ATTCAAACT CACTTTGGTA
 31561 CTTACAAAGT GTGGAAGTCA AATATTAGCT AATGTGTCTT TGATTGTGGT GTCAGGAAAA
 31621 TATCAATACA TAGACCACGC TACAAATCCA ACTCTTAAAT CATTTAAAAT AAAACTTCTT
 31681 TTTGATAATA AAGGTGTACT TCTCCCAAGT TCAAACCTTG ATTCCACATA TTGGAACCTT
 31741 AGAAGTGACA ATTTAACTGT ATCTGAGGCA TATAAAAAATG CAGTTGAATT TATGCCTAAT
 31801 TTGGTAGCCT ACCCAAAACC TACCCTGCGC TCTAAAAAAT ATGCAAGGGA TATAGTCTAT
 31861 GGGAACATAT ATCTTGGAGG TTTGGCATAT CAGCCAGTTG TAATTAAGGT TACTTTTAAT
 31921 GAAGAAGCAG ATAGTGCTTA CTCTATAACA TTTGAATTTG TATGGAATAA AGAATATGCC
 31981 AGGGTTGAAT TTGAACCAC TTCCTTTACC TTCTCCTATA TTGCCCAACA ATAAAAGACC
 32041 AATAAACGTG TTTTATTATT CAAATTTTAT GTATCTTTAT TGATTTTAC ACCAGCGCGA
 32101 GTAGTCAATC TCCCACCACC AGCCCAATTC ACAGTGTACA CGGTTCTCTC AGCACGGTGG
 32161 CCTTAAATAA GGAAATGTTT TGATTATTGC GGGAACTGGA CTTGGGGTCT ATAATCCACA
 32221 CAGTTTCTTG ACGAGCCAAA CGGGGATCGG TGATTGAAAT GAAGCCGTCC TCTGAAAAGT
 32281 CATCCAAGCG GGCCTCACAG TCCAGGTCAC AGTCTGGTGG AACGAGAAGA ACGCACAGAT
 32341 TCATACTCGG AAAACAGGAT GGGTCTGTGC CTCTCCATCA GCGCCCTCAG CAGTCTCTGC
 32401 CGCCGGGGCT CGGTGCGGCT GCTGCAAATG GGATCGGGAT CACAAGTCTC TCTAACTATG
 32461 ATCCCAACAG CCTTCAGCAT CAGTCTCTCTG GTGCGTCGAG CACAGCACCG CATCCTGATC
 32521 TCTGCCATGT TCTCACAGTA AGTGCAGCAC ATAATCACCA TGTTATTTCAG CAGCCCATAA
 32581 TTCAGGGTGC TCCAGCCAAA GCTCATGTTG GGGATGATGG AACCACGTG ACCATCGTAC
 32641 CAGATGCGGC AGTATATCAG GTGCCGCCCC CTCATGAACA CACTGCCCAT ATACATGATC
 32701 TCTTTGGGCA TGTCTCTGTT TACAATCTGG CGGTACCAGG GGAAGCGCTG GTTGAACATG
 32761 CACCCGTAAA TGACTCTCCT GAACCACAGC GCCAGCAGGG TGCCTCCCGC CCGACACTGC
 32821 AGGGAGCCAG GGGATGAACA GTGGCAATGC AGGATCCAGC GCTCGTACCC GCTCACCATC
 32881 TGAGCTCTTA CCAAGTCCAG GGTAGCGGGG CACAGGCACA CTGACATACA TCTTTTAAA
 32941 ATTTTATTTT CCTCTGTGGT GAGGATCATA TCCCAGGGGA CTGGAACTC TTGGAGCAGG
 33001 GTAAAGCCAG CAGCACATGG TAATCCACGG ACAGAACTTA CATTATGATA ATCTGCATGA
 33061 TCACAATCGG GCAACAGGGG ATGTTGATCA GTCAGTGAAG CCCTGGTTTC ATCATCAGAT
 33121 CGTGGTAAAC GGGCCCTGCG ATATGGATGA TGGCGGAGCG AGCTGGATTG AATCTCGGTT
 33181 TGCATTGTAG TGGATTCTCT TGCGTACCTT GTCGTACTTC TGCCAGCAGA AATGGGCCCT
 33241 TGAACAGCAT ATACCCCTCC TGCGGCCGTC CTTTCGCTGC TGCCGCTCAG TCATCCAAT
 33301 GAAGTACATC CATTCCTGAA GATTCGTGAG AAGTTCCTCT GCATCTGATG AAATAAAAAA
 33361 CCCGTCCATG CGAATTCCTC TCATCACATC AGCCAGGACT CTGTAGGCCA TCCCCATCCA
 33421 GTTAATGCTG CCTTGCTAT CATTCAGAGG GGGCGGTGGC AGGATTGGAA GAACCATTTT
 33481 TATTCCAAAC GGTCTCGAAG GACGATAAAG TGCAAGTCAC GCAGGTGACA GCGTTCCCTT
 33541 CCGCTGTGCT GGTGGAAACA GACAGCCAGG TCAAAACCCA CTCTATTTTC AAGGTGCTCG
 33601 ACCGTGGCTT CGAGCAGTGG CTCTACGCGT ACATCCAGCA TAAGAATCAC ATTAAGGCT
 33661 GGCCCTCCAT CGATTCATC AATCATCAGG TTACATTCCT GCACCATCCC CAGGTAATTC
 33721 TCATTTTTC AGCCTTGGAT TATCTTACA AATTGTTGGT GTAAATCCAC TCCGCACATG
 33781 TTGAAAAGCT CCCACAGTGC CCCCTCCACT TTCATAATCA GGCAGACCTT CATAATAGAA
 33841 ACAGATCCTG CTGCTCCACC ACCTGCAGCG TGTTCAAAC AACAAGATT CATAAGGTTT
 33901 TGCCCTCCGC CCTGAGCTCG CGCCTCAATG TCAGCTGCAA AAAGTCACTT AAGTCTGGG
 33961 CCACTACAGC TGACAATTCA GAGCCAGGGC TAAGCGTGGG ACTGGCAAGC GTGAGGAAA
 34021 ACTTTAATGC TCCAAAGCTA GCACCAAAAA ACTGCATGCT GGAATAAGCT CTCTTTGTGT
 34081 CTCCGGTGAT GCCTTCCAAA ATGTGAGTGA TAAAGCGTGG TAGTTTTTTC TTTAATCATT
 34141 TGCCTAATAG AAAAGTCTCG TAAATAAGTC ACTAGGACCC CAGGGACCAC AATGTGGTAG

- 38 -

34201 CTTACACCGC GTCGCTGAAA GCATGGT TAGAGATGAG AGTCTGAAAA ACAGAAAGCA
34261 TGCCTAAAC TAAGGTGGCT ATTTTCACTG AAGGAAAAAT CACTCTTTCC AGCAGCAGGG
34321 TACCCACTGG GTGGCCCTTG CGGACATACA AAAATCGGTC CGTGTGATTA AAAAGCAGCA
34381 CAGTAAGTTC CTGTCTTCTT CCGGCAAAAA TCACATCGGA CTGGGTTAGT ATGTCCCTGG
34441 CATGGTAGTC ATTCAAGGCC ATAAATCTGC CCTGATATCC AGTAGGAACC AGCACACTCA
34501 CTTTTAGGTG AAGCAATACC ACCCATGCG GAGGAATGTG GAAAGATTCA GGGCAAAAAA
34561 AATTATATCT ATTGCTAGCC CTTCTGGAC GGGAGCAATC CTCCAGGACT ATCTATGAAA
34621 GCATACAGAG ATTCAGCCAT AGCTCAGCCC GCTTACCAGT AGACAAAGAG CACAGCAGTA
34681 CAAGCGCCAA CAGCAGCGAC TGACTACCCA CTGACTTAGC TCCCTATTTA AAGGCACCTT
34741 AACTGACGT AATGACCAA GGTCTAAAA CCCC GCCAAA AAAACACACA CGCCCTGGGT
34801 GTTTTTGCGA AAACACTTCC GCGTTCTCAC TTCCTCGTAT CGATTTCGTG ACTTGACTTC
34861 CGGGTTCCCA CGTTACGTCA CTTTTGCCCT TACATGTAAC TTAGTCGTAG GCGCCATCT
34921 TGCCACGTC CAAAATGGCT TACATGTCCA GTTACGCCTC CGCGCGACC GTTAGCCGTG
34981 CGTCGTGACG TCATTTGCAT CAACGTTTCT CGGCCAATCA GCAGTAGCCC CGCCCTAAAT
35041 TTAAACCTC ATTTGCATAT TAACTTTGTG TTACTTTGTG GGTATATTA TTGATGATG

ATGTCAAAGAGGCTCCGGGTGGAAGATGACTTCAACCCCGTCTACCCCTA
TGGCTACGCGCGGAATCAGAATATCCCCTTCCTCACTCCCCCCTTTGTCTC
CTCCGATGGATTCAAAAACCTCCCCCCTGGGGTCCTGTCACTCAAACCTGGC
TGACCCAATCACCATAGCCAATGGTGATGTCTCACTCAAGGTGGGAGGGG
GACTTACTTTGCAAGAAGGAAGTCTGACTGTAGACCCTAAGGCTCCCTTG
CAACTTGCAAACAATAAAAACTTGAGCTTGTTTATGTTGATCCATTTGAG
GTTAGTGCCAATAAACTTAGTTTAAAAGTAGGACATGGATTAAAAATATT
AGATGACAAAAGTGCTGGAGGGTTGAAAGATTTAATTGGCAAACCTTGTTGG
TTTAAACAGGGGAAAGGAATAGGCACTGAAAATTTGCAAATACAGATGGT
AGCAGCAGAGGAATTGGTATAAGTGTAAGAGCAAGAGAAGGGTTAACAT
TTGACAATGATGGATACTTGGTAGCATGGAACCCAAAGTATGACACGCGC
ACACTTTGGACAACACCAGACACATCTCCTAATTGCAGGATTGATAAGGA
GAAGGATTCAAACCTCACTTTGGTACTTACAAAGTGTGGAAGTCAAATAT
TAGCTAATGTGTCTTTGATTGTGGTGTGTCAGGAAAATATCAATACATAGACC
ACGCTACAAATCCAACCTTAAATCATTTAAAATAAACTTCTTTTTGATA
ATAAAGGTGTACTTCTCCCAAGTTCAAACCTTGATTCCACATATTGGAAC
TTAGAAGTGACAATTTAACTGTATCTGAGGCATATAAAAATGCAGTTGAA
TTTATGCCTAATTTGGTAGCCTACCCAAAACCTACCACTGGCTCTAAAAAA
TATGCAAGGGATATAGTCTATGGGAACATATATCTTGGAGGTTTGGCATA
TCAGCCAGTTGTAATTAAGGTTACTTTTAATGAAGAAGCAGATAGTGCTTA
CTCTATAACATTTGAATTTGTATGGAATAAAGAATATGCCAGGGGTTGAA
TTTGAAACCACTTCCTTTACCTTCTCCTATATTGCCCAACAATAA

SEQ ID NO:2

SUBSTITUTE SHEET (RULE 26)

Penton17.Seq Length: 1554

```
1  ATGAGGCGTG CGGTGGTGTC TTCCTCTCCT CCTCCCTCGT ACGAGAGCGT
51  GATGGCGCAG GCGACCCTGG AGGTTCGGTT TGTGCCTCCG CGGTATATGG
101 CTCCTACGGA GGGCAGAAAC AGCATTCGTT ACTCGGAGCT GGCTCCGTTG
151 TACGACACCA CTCGCGTGTA CTTGGTGGAC AACAAGTCGG CGGACATCGC
201 TTCCCTGAAC TATCAAAACG ACCACAGCAA CTTCCTGACC ACGGTGGTGC
251 AGAACAACGA TTTCAACCCC GCCGAGGCTA GCACGCAGAC GATAAATTTT
301 GACGAGCGGT CGCGGTGGGG CGGTGATCTG AAGACCATTG TGCACACCAA
351 CATGCCCAAT GTGAACGAGT ACATGTTTAC CAGCAAGTTT AAGGCGCGGG
401 TGATGGTGGC TAGAAAACAC CCACAGGGGG TAGAAGCAAC AGATTTAAGC
451 AAGGATATCT TAGAGTATGA GTGGTTTGAG TTTACCCTGC CCGAGGGCAA
501 CTTTTCCGAG ACCATGACCA TAGACCTGAT GAACAACGCC ATCTTGAAAA
551 ACTACTTGCA AGTGGGGCGG CAAAATGGCG TGCTGGAGAG CGATATTGGA
601 GTCAAGTTTG ACAGCAGAAA TTTCAAGCTG GGCTGGGACC CTGTGACCAA
651 GCTGGTGATG CCAGGGGTCT ACACCTACGA GGCCTTTAC CCGACGTGG
701 TGCTGCTGCC GGGCTGCGGG GTGGACTTCA CAGAGAGCCG CCTGAGCAAC
751 CTCCTGGGCA TTCGCAAGAA GCAACCTTTC CAAGAGGGCT TCAGAAATCAT
801 GTATGAGGAT CTAGAAGGGG GCAACATCCC CGCCCTGCTG GATGTGCCCCA
851 AGTACTTGGA AAGCAAGAAG AAGTTAGAGG AGGCATTGGA GAATGCTGCT
901 AAAGCTAATG GTCCTGCAAG AGGAGACAGT AGCGTCTCAA GAGAGGTTGA
951 AAAGGCAGCT GAAAAAGAAC TTGTTATTGA GCCCATCAAG CAAGATGATA
1001 CCAAGAGAAG TTACAACCTC ATCGAGGGAA CCATGGACAC GCTGTACCGC
1051 AGCTGGTACC TGTCTTATAC CTACCGGGAC CCTGAGAACG GGGTGCAGTC
1101 GTGGACGCTG CTCACCACCC CGGACGTCAC CTGCGGCGCG GAGCAAGTCT
1151 ACTGGTCGCT GCCGGACCTC ATGCAAGACC CCGTCACCTT CCGTTCTACC
1201 CAGCAAGTCA GCAACTACCC CGTGGTCGGC GCCGAGCTCA TGCCCTTCCG
1251 CGCCAAGAGC TTTTACAACG ACCTCGCCGT CTACTCCCAG CTCATCCGCA
1301 GCTACACCTC CCTACCCAC GTCTTCAACC GCTTCCCCGA CAACCAGATC
```

SEQ ID NO: 3

1351 CTCTGCCGTC CGCCCGCGCC CACCATCACC ACCGTCAGTG AAAACGTGCC
1401 TGCTCTCACA GATCACGGGA CGCTACCGCT GCGCAGCAGT ATCCGCGGAG
1451 TCCAGCGAGT GACCGTCACT GACGCCCCTC GCCGCACCTG TCCCTACGTC
1501 TACAAGGCCC TGGGCATAGT CGCGCCGCGT GTGCTTTCCA GTCGCACCTT
1551 CTAA

- 42 -

Claims

1. A chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell.
2. A chimeric adenoviral vector according to Claim 1 wherein said second adenovirus is selected from the group consisting of Ad 9, Ad 15, Ad 17, Ad 19, Ad 20, Ad 22, Ad 26, Ad 27, Ad 28, Ad 30, and Ad 39.
3. A chimeric adenoviral vector according to Claim 1 wherein said first adenovirus is selected from the group consisting of Ad 2, Ad 5, and Ad 12.
4. A chimeric adenoviral vector according to Claim 1 wherein said replaced gene encodes Ad fiber.
5. A chimeric adenoviral vector according to Claim 1 wherein said replaced gene encodes Ad penton base.
6. A chimeric adenoviral vector according to Claim 1 wherein a first replaced gene encodes Ad fiber, and a second replaced gene encodes Ad penton base.
7. A chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization

- 43 -

thereof within said cell, is replaced by a portion of the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell.

5

8. A chimeric adenoviral vector according to Claim 7 wherein the encoding sequence that is replaced codes for a portion of Ad fiber.

9. A chimeric adenoviral vector according to Claim 7 wherein the encoding sequence that is replaced codes for a portion of Ad penton base.

10. A chimeric adenoviral vector according to Claim 9 wherein the encoding sequence that is replaced codes for an amino acid sequence that includes RGD.

11. A method of providing a biologically active protein to the airway epithelial cells of a patient comprising administering to said cells an adenoviral vector selected from the group consisting of:

(a) a chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein at least one gene of said first adenovirus encodes a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by the corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell; and

25

(b) a chimeric adenoviral vector comprising nucleotide sequence of a first adenovirus, wherein a portion of a gene thereof encoding a protein that facilitates binding of said vector to a target mammalian cell, or internalization thereof within said cell, is replaced by a portion of the

- 44 -

corresponding gene from a second adenovirus belonging to subgroup D, said vector further comprising a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell;

5 under conditions whereby the transgene encoding said protein is expressed, and phenotypic benefit is produced in said airway epithelial cells.

12. A method according to Claim 11 wherein said second adenovirus is Ad 17 and the nucleotide sequence thereof used in replacement of nucleotide sequence of
10 said first adenovirus encodes a polypeptide selected from the group consisting of Ad 17 fiber, a fragment of Ad 17 fiber, Ad 17 hexon, a fragment of Ad 17 hexon, Ad penton base, and a fragment of Ad 17 penton base.

13. A method of providing a biologically active protein to the airway epithelial
15 cells of a patient that comprises administering to said cells an adenoviral vector comprising elements of an Ad 17 genome, and a transgene encoding said protein that is operably linked to a eucaryotic promoter to allow for expression therefrom in a mammalian cell, under conditions whereby the transgene encoding said protein is expressed, and phenotypic benefit is
20 produced in said airway epithelial cells.

1/17




FIG 1 - original filed in PTO
is full color - see side Solder

2/17




FIG 2 - original filed in FTO
is full color - see side folder




FIGURE 3

4/17


Chimeric Ad2/ β gal-2/ Ad17 vectors

FIGURE 4

5/17

```

1  MRRAVVSSPPPPSYESVMA.....QATLEVFPVPPRYMAPTEGR 39      SEQ ID NO:4
   | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
MQ RAAMYEEGPPPSYESVVSAAAPVAAALGSPFDAPLDPFFVPVPRYL RPTGGR 52      SEA ID NO:5
40 NSIRYSELAPLYDTRVYLVDNKSADIASLNYQNDHSNFLTTVVQNNDF 79
   | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
53 NSIRYSELAPLFDTRVYLVDNKSTDVASLNYQNDHSNFLTTVIQNNDS 102
90 PAEASTOTINFDRSRWGGDLKTI LHTNMPNVNEYMF TSKFKARVMVARK 139
   | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
103 PGEASTOTINLDDRSHWGGDLKTI LHTNMPNVNEFMF TNKFKARVMVSR 152
140 HPQGEATDLSKDI LEYEWFEFTLPEGNFSE TMTIDL MNNAILENYLQV 189
   | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
153 LTKDKQVE..... LKYEWFEFTLPEGNYSE TMTIDL MNNAIVEHYLKV 196
190 RQNGVLES DIGVKFDSRNFKLGWDPVTKLVMPGVYTYEAFHPDVLLPGC 239
   | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
197 RQNGVLES DIGVKFDTNRNFR LGFDPVTGLVMPGVYTNEAFHPDIILLPGC 246
240 GVDFTESRLSNLLGIRKKOPFQEGFRIMYEDLEGGNIPALLDVPKYLE. 288
247 GVDFTESRLSNLLGIRKKOPFQEGFRITYDDLEGGNIPALLDVPDAYQASL 296
289 KKKLEEALENA AAKANGPA.....RGDSSVS 313
   | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
297 KDDTEQGGD GAGGGNNSGSGAEENS NAAAAA MQPVEDMNDHAI RGDTFAT 346
314 REVEKAAE.....KELVIEPIKODDTKRSYNLIEG 343
   | : : : : : | : : : : : | : : : : : | : : : : : | : : : : : |
347 RAE EKRAEAEAAAAEAAAPAAOPEVEKPOKKPVIKPLTEDSKKRSYNLISN 396
344 TMD.TLYRSWYLSYTYRDPENGVCSTLLTTPDVTGCAEQVYWSLPDLMQ 392
397 DSTFTQYRSWYLAYN'YGDPO TGIRSWTLLCTPDVTGCGSEQVYWSLPDLMQ 446

```

FIGURE 5A

6/17

393 DPVTFRSTQOVSNYPVVGAELMPFRAKSFYNDLAVYSQLIRSYTSLTHVF 442
||||| :|||:|||||:|..| ||||| :|||||
447 DPVTFRSTSQISNFPVVGAELLPVHKSIFYNDQAVYSQLIRQFTSLTHVF 496
443 NRFPDNQILCRPPAPTITTVSENPALTDHGTPLRSSIRGVQRVTVTDA 492
|||:||||.||||| ||||| |||||:|
497 NRFPENQILARPPAPTITTVSENPALTDHGTPLRNSIGGVQRVTTITDA 546
493 RRRTCPYVYKALGIVAPRVLSSRTF 517
||||| |||||
547 RRRTCPYVYKALGIVSPRVLSSRTF 571

FIGURE 5B

7/17

//

	1		50	
Penton5	...MRRAAM.YEEGP	PPSYESVUSA ..APVAAALG	SPFDAPLDPP	← SEQ ID NO: 6
Penton2	...MORAAM.YEEGP	PPSYESVUSA ..APVAAALG	SPFDAPLDPP	← SEQ ID NO: 5
Penton3	..MRRRAVLG GAV.VYPEGP	PPSYESVM..QQQA	AMIQPPLEAP	← SEQ ID NO: 7
Penton12	...MRRRAVEL QTV.AFPETP	PPSYETVM..AAAPP		← SEQ ID NO: 8
Penton40	...MRRRAVGVPVMAYAE	PPSYESVM..ET	ADLPATLQAL	← SEQ ID NO: 9
Penton17	...MRRRAVV.SSSP	PPSYESVM..A...	...QATLEVP	← SEQ ID NO: 4
Pentonf10	MWGLQPPTSI PPPPPTELT	PSTYPAMVNG YPPPAASAQS	CSSSGGQSEL	← SEQ ID NO: 10
	51		100	
Penton5	FVP.PRYLRP TGGRNSIRYS	ELAPLFDTR VYLVDNKSTD	VASLNYQNDH	
Penton2	FVP.PRYLRP TGGRNSIRYS	ELAPLFDTR VYLVDNKSTD	VASLNYQNDH	
Penton3	FVP.PRYLAP TEGRNSIRYS	DVSPLYDTTK LYLVDNKSAD	IASLNYQNDH	
Penton12	YVP.PRYLGP TEGRNSIRYS	ELSPLYDTTK VYLVDNKSAD	IASLNYQNDH	
Penton40	HVP.PRYLGP TEGRNSIRYS	ELAPLYDTTK VYLVDNKSAD	IASLNYQNDH	
Penton17	FVP.PRYMAP TEGRNSIRYS	ELAPLYDTTK VYLVDNKSAD	IASLNYQNDH	
Pentonf10	YMPLQVRMAP TGGRNSIKYR	DYTPCRNTTK LFYVDNKASD	IDTYNKDANH	
	101		150	
Penton5	SNFLTTVIQN NDYSPGEAST	QTINLDDRS WGGDLKTILH	TNMPNVNEFM	
Penton2	SNFLTTVIQN NDYSPGEAST	QTINLDDRS WGGDLKTILH	TNMPNVNEFM	
Penton3	SNFLTTVVQN NDFTPEAST	QTINFDRSR WGGQLKTIMH	TNMPNVNEYM	
Penton12	SNFLTTVVQN NDYSPIEAGT	QTINFDRSR WGGDLKTILH	TNMPNVNDFM	
Penton40	SNFQTTVVQN NDFTPEAGT	QTINFDRSR WGGDLKTILR	TNMPNINEFM	
Penton17	SNFLTTVVQN NDFTPAEAST	QTINFDRSR WGGDLKTILH	TNMPNVNEYM	
Pentonf10	SNFRTTVIHN QDLADTAAT	ESIQLDNRSC WGGDLKTAVR	TNCPNVSSFF	
	151		200	
Penton5	FTNKFKARVM VSRL.....	...PTKD..N QVELKYEWVE	FTLPEGNYSE	
Penton2	FTNKFKARVM VSRS.....	...LTKD..K QVELKYEWVE	FTLPEGNYSE	
Penton3	FSNKFKARVM VSRKAPEGVT	VNDTYDH..K EDILKYEWFE	FILPEGNFSA	
Penton12	FTTKFKARVM VARK.....	...TNNE..G QTILEYEWAE	FVLPEGNYSE	
Penton40	STNKFRARVM VEK.....	...VNR..K TNAPRYEWFE	FTLPEGNYSE	
Penton17	FTSKFKARVM VARKHPQGV	..EATDL..S KDILEYEWFE	FTLPEGNFSE	
Pentonf10	QSNSVRVRMM WKRDPTSTA	PPSAVGSGYS VPGAQYKWD	LTVPEGNYAL	
	201		250	
Penton5	TMTIDLNMNA IVEHYLKVGR	ONGVLESIDG VKFDTRNFRL	GFDPTGLVM	

FIGURE 6A

8/17

Penton2	TMTIDLMNNA	IVEHYLAJGR	QNGVLESDIG	VKFDTRNFRL	GFDPVTKLVM
Penton3	TMTIDLMNNA	IIDNYLEIGR	QNGVLESDIG	VKFDTRNFRL	GWDPETKLIM
Penton12	TMTIDLMNNA	IIHYLRVGR	QHGVSLESDIG	VKFDTRNFRL	GWDPETQLVT
Penton40	TMTIDLMNNA	IVDNYLAVGR	QNGVLESDIG	VKFDTRNFRL	GWDPVTKLVM
Penton17	TMTIDLMNNA	ILENYLOVGR	QNGVLESDIG	VKFDTRNFRL	GWDPVTKLVM
Pentonf10	CELIDLLNEG	IVQLYLSEGR	QNNVQKSDIG	VKFDTRNFGL	LKDPVTGLVT
251			300		
Penton5	PGVYTNEAFH	PDIILLPGCG	VDFTHSRLSN	LLGIRKRQPF	QEGFRITYDD
Penton2	PGVYTNEAFH	PDIILLPGCG	VDFTHSRLSN	LLGIRKRQPF	QEGFRITYDD
Penton3	PGVYTYEAFH	PDIIVLLPGCG	VDFTESRLSN	LLGIRKRHPF	QEGFKIMYED
Penton12	PGVYTNEAFH	PDIIVLLPGCG	VDFTESRLSN	ILGIRKRQPF	QEGFVIMYEH
Penton40	PGVYTNEAFH	PDIIVLLPGCG	VDFTSRLSN	LLGIRKRMPF	QKGFQIMYED
Penton17	PGVYTYEAFH	PDVLLPGCG	VDFTESRLSN	LLGIRKRQPF	QEGFRIMYED
Pentonf10	PGTYVYKGYH	PDIIVLLPGCA	IDFTYSRLSL	LLGIGKREPY	SKGFVITYED
301			350		
Penton5	LEGGNIPALL	DVDAYQASLK	DDTEQGGGGA	GGSNSSGSGA	EENSNAAAAA
Penton2	LEGGNIPALL	DVDAYQASLK	DDTEQGGDGA	GGGNSSGSGA	EENSNAAAAA
Penton3	LEGGNIPALL	DVTAYEESKK	DTTETTTTLA	VAEETSE...
Penton12	LEGGNIPALL	DVKKYENSL	Q...
Penton40	LEGGNIPALL	DVEKYEASIK
Penton17	LEGGNIPALL	DVPKYLESKK	KLE.....	E ALENAAK...
Pentonf10	LQGGDIPALL	DLDSVDVND	DGEVIELDNA	A.....
351			400		
Penton5	MQPVEDMNDH	AIRGDTFATR	AEEKRAEAEA	AAEAAAAPAAQ	PEVEKPQKKP
Penton2	MQPVEDMNDH	AIRGDTFATR	AEEKRAEAEA	AAEAAAAPAAQ	PEVEKPQKKP
Penton3	DDD ITRGDTYITE	KQKREAAAAE	V.....KKEL
Penton12	DQN TVRGDNFIA	L.....NKA
Penton40	EAQ EIRGADFKPN	PQ.....DL
Penton17	ANG PARGDSSVSR	EVEKAA....EKEL
Pentonf10
401			450		
Penton5	VIKPLTEDSK	KRSYNLI...	SNDSTFTQYR	SWLAYNYGD	PQTGIRSWTL
Penton2	VIKPLTEDSK	KRSYNLI...	SNDSTFTQYR	SWLAYNYGD	PQTGIRSWTL
Penton3	KIQPLEKDSK	SRSYNVL...	E.DKINTAYR	SWLSYNYGN	PEKGIRSWTL
Penton12	RIEPVETDPK	GRSYNLL...	P.DKKNTKYR	SWLAYNYGD	PEKGVRSWTL
Penton40	EIVPVEKDSK	ERSYNLL...	EGDKNNTAYR	SWFLAYNYGD	AEKGVKSWTL
Penton17	VIEPIKQDDT	KRSYNLI...	E.GTMDTLYR	SWLSYTYRD	PENGVSQSWTL
Pentonf10	...PLLHDSA	GVSYNVIYDQ	VTGKPVTAIR	SWMLAYNVFN	SQANQT..TL
451			500		
Penton5	LCTPDVTCGS	EQVYWSLPDM	MQDPVTFRST	RQISNFPVVG	AELLPVHSKS
Penton2	LCTPDVTCGS	EQVYWSLPDM	MQDPVTFRST	SQISNFPVVG	AELLPVHSKS
Penton3	LTTSDVTCGA	EQVYWSLPDM	MQDPVTFRST	RQVNNYPVVG	AELMPVFSKS
Penton12	LTPPDVTCGS	EQVYWSLPDM	MQDPVTFRST	RQVSNYPVVA	AELLPVHAKS
Penton40	LTTTDVTCGS	QVYWSLPDM	MQDPVTFRPS	TQVSNYPVVG	VELLPVHAKS
Penton17	LTPPDVTCGA	EQVYWSLPDL	MQDPVTFRST	QVSNYPVVG	AELMPFRKS
Pentonf10	LTVPDMAGGI	GAMYSLSLPT	FIAPTGFKE	NTTNLCPUVG	MNLFPTYNKI
501			550		
Penton5	FYNDQAVYSQ	LIRQFT.SLT	HVFNRFPENQ	ILARPPAPTI	TTVSENVPAL
Penton2	FYNDQAVYSQ	LIRQFT.SLT	HVFNRFPENQ	ILARPPAPTI	TTVSENVPAL
Penton3	FYNEQAVYSQ	QLRQAT.SLT	HVFNRFPENQ	ILIRPPAPTI	TTVSENVPAL
Penton12	FYNEQAVYSQ	LIRQST.ALT	RVFNRFPENQ	ILVRPPAATI	TTVSENVPAL

FIGURE 6B

9/17

Penton40 FYNEQAVYSQ LIRQST.ALT HIFNRFPENQ ILVRPPAPTI TTVSENV~~F~~AL
Penton17 FYNDLAVYSQ LIRSYT.SLT HVFNRFDPNQ ILCRPPAPTI TTVSENV~~F~~PAL
Pentonf10 YYQAASTYVQ RLENSCQSAT AAFNRFPENE ILKQAPPMNV SSVCDNQPAV

551

600

Penton5 TDHGTLP~~L~~RN SIGGVQ~~R~~VTI TDARRR~~T~~CPY VYKALGIVSP RVLSSRTF*.
Penton2 TDHGTLP~~L~~RN SIGGVQ~~R~~VTI TDARRR~~T~~CPY VYKALGIVSP RVLSSRTF*.
Penton3 TDHGTLP~~L~~RS SIRGVQ~~R~~VTV TDARRR~~T~~CPY VYKALGIVAP RVLSSRTF*.
Penton12 TDHGTLP~~L~~RS SISGVQ~~R~~VTI TDARRR~~T~~CPY VYKALGIVSP RVLSSRTF*.
Penton40 TDHGTLP~~L~~RS SISGVQ~~R~~VTI TDARRR~~T~~CPY VHKALGIVAP KVLSSRTF*.
Penton17 TDHGTLP~~L~~RS SIRGVQ~~R~~VTV TDARRR~~T~~CPY VYKALGIVAP RVLSSRTF*.
Pentonf10 VQQGVLPVKS SLPGLQ~~R~~VLI TDDQRRPIPY VYKSIATVQP TVLSSATLQ*

FIGURE 6C

Fiber17.Pep x Fiber2.Pep

FIGURE 7A

FIGURE 7A

11/17

236 ATNPTLKSFKIKLLFDNKGVLPLSSNLDSTYWNFRSDNLTVSEAYKNAVE 285
...|:|...| | |...|:|...|...| | | | |...| |...|:|...| |
447 SMTGTVASVSIFLRFDQNGVLMENSSLKKHYWNFRNGNSTNANPYTNAVG 496
286 FMPNLVAYPKPTTGSKKYARDIVYGNLYLGGGLAYQPVVIKVTFNNEAD.. 333
| | | | | : | | | | |...| : : : : : | |...| : : : : : | : : : : :
497 FMPNLLAYPKTQSQT...AKNNIVSQVYLHGDKTKPMILTITLNGTSEST 543
334SAYSITFEFVNKE.YARVEFETTSFTFSYIAQQ 366
|.||:|. |: |:|. |. |. |. | : | | | | | :
544 ETSEVSTYSMSFTWSWESGKYTTTETTFATNSYTF SYIAQE 582

FIGURE 7B

12/17

	1				50
8fiber	MTKRLRA...EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSNGFQNF - SEQ ID NO:13
9fiber	MSKRLRV...EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSDGFQNF - SEQ ID NO:14
15fiber	MSKRLRV...EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSDGFQNF - SEQ ID NO:15
17fiber	MSKRLRV...EDDFN	PVYPYGYARN	Q.NIPFLTPP	FVSSDGFQNF - SEQ ID NO:11
2fiber	.MKRARP...SEDTFN	PVYPYDTETG	PPTVPFLTPP	FVSPNGFQES - SEQ ID NO:12
5fiber	.MKRARP...SEDTFN	PVYPYDTETG	PPTVPFLTPP	FVSPNGFQES - SEQ ID NO:16
4fiber	MSKSARG...WSDGFD	PVYPYDADND	RP.CPSSTLP	SFSSDGFQEK - SEQ ID NO:17
40-1fiber	.MKRTRIE..DDFN	PVYPYD.TSS	TPSIPYVAPP	FVSSDGLQEN - SEQ ID NO:18
41fiber	.MKRTRIE..DDFN	PVYPYD.TFS	TPSIPYVAPP	FVSSDGLQEK - SEQ ID NO:19
40-2fiber	.MKRARFE..DDFN	PVYPYE.HYN	PLDIPFITPP	FASSNGLQEK - SEQ ID NO:20
12fiber	.MKRSRTQYA	EETEENDDFN	PVYPFD.PFD	TSDVFFVTPP	FTSSNGLQEK - SEQ ID NO:21
3fiber	MAKRARL...STSFN	PVYPYEDESS	SQH.PFINPG	FISPDGFTQS - SEQ ID NO:22
	51				100
8fiber	PPGVLSLKLA	DPITIN.NGN	VSLKVGGLT	LQEET.....	
9fiber	PPGVLSLKLA	DPIAIV.NGN	VSLKVGGLT	LQDGT.....	
15fiber	PPGVLSLKLA	DPIAIA.NGN	VSLKMGGLT	LQEGT.....	
17fiber	PPGVLSLKLA	DPITIA.NGD	VSLKVGGLT	LQE.....	
2fiber	PPGVLSLRVS	EPLDTS.HGM	LALKMGGLT	LDKAGNLTQ	NVTTVTQPLK
5fiber	PPGVLSRLS	EPLVTS.NGM	LALKMGGLT	LDEAGNLTQ	NVTTVSPPLK
4fiber	PLGVLSLPG	RPCHTK.NGE	ITLKLGEVD	LDDSGKLIAN	TVNKAIAPL.
40-1fiber	PPGVLALKYT	DPITTNAKHE	LTLKLGSNIT	LQ.NGLLSA.	
41fiber	PPGVLALKYT	DPITTNAKHE	LTLKLGSNIT	LE.NGLLSA.	
40-2fiber	PPGVLSLKYT	DPLTTK.NGA	LTLKLGTGLN	IDKNGDLSSD	ASVEVSAPIT
12fiber	PPGVLALNYK	DPIVTE.NGT	LTLKLGDGIK	LNAQGQLTAS	NNINVLEPLT
3fiber	PNGVLSLKCV	NPLTTA.SGS	LQLKVGGLT	VD.....	
	101				150
8fiber	
9fiber	
15fiber	
17fiber	

FIGURE 8A

13/17

2fiber	KTKSNISLDA	S	LTITSGA	LTVATTAPLI	VTSGALS	QAPLTVQDSK
5fiber	KTKSNINLEI	SAPLTVTSEA	LTVAAAAPLM	VAGNTLTMQS	QAPLTVHDSK	
4fiberSFFQQH	HFPL.....	
40-1fiber	
41fiber	
40-2fiber	KTNKIVGLNY	TKPLALONNA	LTLSYNAPFN	VVNNNLALNM	SQPVTI....	
12fiber	NTSQGLKLSW	SAPLAVKASA	LTNTRAPLT	TTDESLALIT	APPITVESSR	
3fiber	
	151				200	
8fiber	
9fiber	
15fiber	
17fiber	
2fiberLSI	
5fiberLSI	
4fiber	
40-1fiber	
41fiber	
40-2fiber	NANNELSLL	IDAPLNADTG	TLRLRSDAPL	GLVDK.TLKV	
12fiber	LGLATIAPLS	LDGGGNLGLN	LSAPLDVSNN	NLHLTTETPL	VVNSSGALSV	
3fiber	
	201				250	
8fiberGKLT	VNTEPPLH..	
9fiberGKLT	VNADPPLQ..	
15fiberGNLT	VNTEPPLQ..	
17fiberGSLT	VDPKAPLQ..	
2fiber	ATKGPI TVSD	GKLALQTSAP	LSGSDSDTLT	VTASPPLTTA	TGSLGINMED	
5fiber	ATQGPLTVSE	GKLALQTSAP	LTSTDSTLT	ITASPPLTTA	TGSLGIDLKE	
4fiberTWIP	LYTPKMENYP	YKFLPPLSIL	KSTI.....	
40-1fiberTVPT...VSPPLTNS	NNSLGLATSA	
41fiberTVPT...VSPPLTNS	NNSLGLATSA	
40-2fiber	LFSSPLYLDN	NFLTIAIERP	LALSSNRAVA	LKYSPPPLKIE	NENLTLSTGG	
12fiber	ATADPISVRN	NALTLPTADP	LMVSSD.GLG	ISVTSPITVI	NGSLALSTTA	
3fiber	
	251				300	
8fiber	..LTNN.KLG	IALDAPFDVI	D..NKLTLLA	GHGLSII.TK	ETSTLPGLVN	
9fiber	..LTNN.KLG	IALDAPFDVI	D..NKLTLLA	GHGLSII.TK	ETSTLPGLRN	
15fiber	..LTNN.RIG	IALDAPFDVI	G..GKLTLLA	GHGLSII.TE	ETSPLPGLVN	
17fiber	..LANKKLE	LVYVDPFEVS	A..NKLSLKV	GHGLKILDDK	SAGGLKDLIG	
2fiber	PIYVNNKGIG	IKISGPLQVA	QNSDTLTVVT	GPGVTVEQNS	LRTKVAGAIG	
5fiber	PIYTQNGKLG	LKYGAPLHVT	DDLNTLTVAT	GPGVTINNTS	LQTKVTGALG	
4fiberLNTLVSAF	GSGLGLSGSA	LAVQLASPLT	
40-1fiber	PIAVSANSIT	LATAAPLTVS	N..NQLSINT	GRGLVITNNA	VAVNPTGALG	
41fiber	PIAVSANSIT	LATAAPLTVS	N..NQLSINA	GRGLVITNNA	LTVNPTGALG	
40-2fiber	PFTVSGGNLN	LATSAPLSVQ	N..NSLSLGV	NPPFLITDSG	LAMDLDGDLA	
12fiber	PLNSTGSTLS	LSVANPLTIS	Q..DTLTVST	GNGLQVSGSQ	LVTRIGDGLT	
3fiber	...TTDGSLE	ENIKVNTPLT	KSNHSINLPI	GNGLQIEQNK	LCS.....	
	301				350	
8fiber	
9fiber	
15fiber	
17fiber	
2fiber	YDSSNNMEIK	TGGGMRIN..	NNLLILDVDY	PFDAQTKLRL	KLGGQPLYIN	

FIGURE 8B

14/17

5fiber	FDSQGNMQLN	JA	JLRIDSQ	NRRILIDVSY	PFDAQNQL	RLGQGPLFIN
4fiber	FDDKG.....					
40-1fiber	FNNTGALQLN	AAGGMRVDGA	N..LILHVAY	PFEAINQLTL	R.....	
41fiber	FNNTGALQLN	AAGGMRVDGA	N..LILHVAY	PFEAINQLTL	R.....	
40-2fiber	LGG.SKLIIN	LGPGLQMSNG	A..ITL....	ALDAALPL..Q	
12fiber	FDN.GVMKVN	VAGGMRTSGG	R..IILDVNY	PFDAENNLSL	RRGLGLIYNQ	
3fiber					
	351					400
8fiber				TLVVLTGKGI	
9fiber				TLVVLTGKGI	
15fiber				TLVVLTGKGL	
17fiber				KLVVLTGKGI	
2fiber	ASHNLDINYN	RGLYLFNASN	NTKKLEVSIX	KSSGLNFDNT	AIAINAGKGL	
5fiber	SAHNLDINYN	KGLYLFNASN	NSKKLEVNLS	TAKGLMFDAT	AIAINAGDGL	
4fiber	...NIKITLN	RGLHVTGDA	...IESNIS	WAKGIKFEDG	AIATNIGKGS	
40-1fiber					
41fiber					
40-2fiber	YKNN.....				..QLQLRIGS	
12fiber	STNW.....				..NLTTDIST	
3fiber					
	401					450
8fiber	GTDLSNNGG.	...NICVRVG	E.....GGGLS	FNDNGDLVAF	
9fiber	GTESTDNNGG.	...TVCVRVG	E.....GGGLS	FNDNGDLVAF	
15fiber	GTDTTDNNGG.	...SIRVRVG	E.....GGGLS	FNEAGDLVAF	
17fiber	GTENLQNTDG	SSRGIGISVR	A.....REGLT	FDNDGYLVAV	
2fiber	EFDINTSESP	DINPIKTKIG	SGIDYNGENGA	MITKLGAGLS	FDNSGAITIG	
5fiber	EFG..SPNAP	NTNPLKTKIG	HGLEFDSNKA	MVPKLGAGLS	FDSTGAITVG	
4fiber	RFGTSSTETG	VNNAYPIQV.KLGSGLS	FDSTGAIMAG	
40-1fiberLE	NGLEVTNGGK	LNKVLGSGLQ	FDNNGRITIS	
41fiberLE	NGLEVTSGGK	LNKVLGSGLQ	FDSNGRIAIS	
40-2fiber	ASALIMSGVT	QTLNVNANTS	KGLAIENNS.	LVVKLGNGLR	FDSWGSTAVS	
12fiber	EKGLMFSGN.	...QIALNAG	OGLTFNNGQ.	LRVKLGAGLI	FDSNNNIALG	
3fiberKLGNGLT	FDSSNSIALK	
	451					500
8fiber	NKKEDK....	.RTLWTTTPTD	SPNCRID...	QDKDSKLSLV	LTKCGSQILA	
9fiber	NKKEDK....	.RTLWTTTPTD	SPNCKID...	QDKDSKLTIV	LTKCGSQILA	
15fiber	NKKEDM....	.RTLWTTTPTD	SPNCKII...	EDKDSKLTIV	LTKCGSQILG	
17fiber	NPKYDT....	.RTLWTTTPTD	SPNCRID...	KEKDSKLTIV	LTKCGSQILA	
2fiber	NKNDDK....	.LTLWTTTPTD	SPNCRID...	SDNDCKFTLV	LTKCGSQVLA	
5fiber	NKNDDK....	.LTLWTTTPTD	SPNCRID...	AEKDAKLTIV	LTKCGSQILA	
4fiber	NKDYDK....	.LTLWTTTPTD	SPNCQIL...	AENDAKLTLC	LTMCDSQILA	
40-1fiber	NRIQTRSVTS	LTTIWSIS.P	TPNCSIY...	ETQDANLFLC	LTKNGAHVLG	
41fiber	NSNRTRSVPS	LTTIWSIS.P	TPNCSIY...	ETQDANLFLC	LTKNGAHVLG	
40-2fiber	PTTTT...P.	.TTLWTTADP	SPNATFY...	ESLDAKVVLV	LVKCNMGVNG	
12fiber	SSSNTPYDP.	.LTLWTTTPTD	PPNCSLI...	QELDAKLTLC	LTKNGSIVNG	
3fiber	NN.....	..TLWTGPKP	EANCIIEYGK	QNPDSKLTIV	LVKNGGIVNG	
	501					550
8fiber	NVSLIVVAGR	YKIIINNNTNP	..ALKGFTIK	LLFDKNGVLM	ESSN.....	
9fiber	NVSLIVVDGK	YKIIINNNTNP	..ALKGFTIK	LLFDKNGVLM	ESSN.....	
15fiber	SVSLIVVKGK	FSNINNNTNP	NEADKQITVK	LLFDANGVLK	QGST.....	
17fiber	NVSLIVVSGK	YQYIDHATNP	..TLKSFKIK	LLFDKNGVLL	PSSN.....	
2fiber	TVAALAV.S.GDLSSM	TGTVASVSIF	LRFDQNGVLM	ENSS.....	
5fiber	TVSVLAV.K.GSLAPI	SGTVQSAHLI	IRFDKNGVLL	NNSF.....	

FIGURE 8C

15/17

4fiber	TVSVLVVRS.	..	GNLNPI	TGTVSSAQVF	LRFDANGV	TEHS.....
40-1fiber	TITIKGLKGA	LREMNDNA..LSVK	LPFDNQGNLL	NCA.....	
41fiber	TITIKGLKGA	LREMHDNA..LSLK	LPFDNQGNLL	NCA.....	
40-2fiber	TISIKAQKGT	LL..KPTASFISFV	MYFYSDGTWR	KNYPVFDNEG	
12fiber	IVSLVGKGN	LLNIQSTTTTVGVH	LVFDEQGRLI	TSTP.....T	
3fiber	YVTLMGASDY	VNTLFKNKNVSINVE	LYFDATGHIL	PDSSSLKTDL	
551						
8fiber	..LGKSYWNF	RNQNSIMSTA	YEKAIGFMPN	LVAYPKPTTG	SKKY...ARD	
9fiber	..LGKSYWNF	RNENSIMSTA	YEKAIGFMPN	LVAYPKPTAG	SKKY...ARD	
15fiber	..MDSSYWNF	RSDNSNLSQP	YKKAUGFMPN	KTAYPKQTKP	TNKEISQAKN	
17fiber	..LDSTYWNF	RSDNLTVSEA	YKNAVEFMPN	LVAYPKPTTG	SKKY...ARD	
2fiber	..LKKHYWNF	RNGNSTNANP	YTNAVGFMPN	LLAYPKTQSQ	T.....AKN	
5fiber	..LDPEYWNF	RNGDLTEGTA	YTNAVGFMPN	LSAYPKSHGK	T.....AKS	
4fiber	..TSKKYWG	KQGDSIDGTP	YTNAVGFMPN	STAYPKTQSS	T.....TKN	
40-1fiber	..LESSTWRY	QETNAVA...	..SNALTFMPN	STVYPRNKTA	D.....PGN	
41fiber	..LESSTWRY	QETNAVA...	..SNALTFMPN	STVYPRNKTA	H.....PGN	
40-2fiber	ILANSATWGY	RQGQSANTN.	VSNAVEFMPN	SKRYPNEKGS	E.....VQN	
12fiber	ALVPQASWGY	RQGQSVSTNT	VTNGLGFMPN	VSAYPRPNAS	E.....AKS	
3fiber	ELKYKQTADFSARGFMPN	TTAYPFVLPN	AGTH...NEN	
601						
8fiber	IVYGNILG	KPHQ..PVTI	KTFNQETG.CEYS	ITFDFSWAKT	
9fiber	IVYGNILG	KPDQ..PVTI	KTFNQETG.CEYS	ITFDFSWAKT	
15fiber	KIVSNVYL	KIDQ..PCVI	IISFNED.SDYS	IVFYFKWYKT	
17fiber	IVYGNILG	LAYQ..PVVI	KVTFNEED.SAYS	ITFEFVWNKE	
2fiber	NIVSQVYL	DKTK..PMIL	TITLNGTSES	TETSEVSTYS	MSFTWSWESG	
5fiber	NIVSQVYL	DKTK..PVTI	TITLNGTQET	GDTT.PSAYS	MSFSWDWSGH	
4fiber	NIVSQVYM	DVSK..PMLL	TITLNGTDDT	T.....SAYS	MSFSYTWTNG	
40-1fiber	MLI.....	QISP..NITF	SVVYNEINS.GYA	FTFKW.SAEP	
41fiber	MLI.....	QISP..NITF	SVVYNEINS.GYA	FTFKW.SAEP	
40-2fiber	MALTYTFLQ	DPNM..AISF	QSIYN..HA.IEGYS	LKFTW.RVRN	
12fiber	QMVSLTYLQ	DTSK..PITM	KVAFNGITS.LNGYS	LTFMW.SGLS	
3fiber	YIFGQCYKA	SDGALFPLEV	TVMLNKRLPD	SRTSYVMTFL	WSLNAGLAPE	
651						
8fiber	.YVNVEFETT	SFTFSYIAQE	*			
9fiber	.YVNVEFETT	SFTFSYIAQE	*			
15fiber	.YENVQFDSS	SFNFSYIAQE	*			
17fiber	.YARVEFETT	SFTFSYIAQQ	*			
2fiber	KYTTETFATN	SYTFSYIAQE	..			
5fiber	NYINEIFATS	SYTFSYIAQE	*			
4fiber	SYIGATFGAN	SYTFSYIAQQ	*			
40-1fiber	...GKPFHPP	TAVFCYITEQ	*			
41fiber	...GKPFHPP	TAVFCYITEQ	*			
40-2fiber	...NERFDIP	CCSFSYVTEQ	*			
12fiber	NYINQPFSTP	SCSFSYITQE	*			
3fiber	T.TQATLITS	PFTFSYIRED	D*			
672						

FIGURE 8D

16/17





FIGURE 9

17/17

Cancer Cell Lines



EXAMPLE 10

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/21494

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/86 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	P.W. ROELVINK ET AL.: "Comparative analysis of adenovirus fiber-cell interaction: Ad2 and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment" JOURNAL OF VIROLOGY, vol. 70, no. 11, November 1996, AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 7614-7621, XP002062100 see page 7620, last paragraph	1-13
A	WO 96 26281 A (GENVEC INC ; CORNELL RES FOUNDATION INC (US)) 29 August 1996 see example 7	1,4,6-8, 10,11
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

14 April 1998

Date of mailing of the international search report

12.04.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 eponl,
Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/21494

C.(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. GALL ET AL: "Adenovirus type 5 and 7 capsid chimera: Fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes" JOURNAL OF VIROLOGY., vol. 70, no. 4, April 1996, pages 2116-2123, XP002050655 see the whole document ---	1,4,6-8, 10,11
P,X	WO 97 12986 A (CORNELL RES FOUNDATION INC) 10 April 1997 see page 15, line 1 - line 7 -----	1,2,13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/21494

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11 to 13
because they relate to subject matter not required to be searched by this Authority, namely:
Although these claims are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the adenoviral vector
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No
PCT/US 97/21494

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9626281 A	29-08-96	AU 4980496 A CA 2213343 A EP 0811069 A	11-09-96 29-08-96 10-12-97
-----	-----	-----	-----
WO 9712986 A	10-04-97	NONE	
-----	-----	-----	-----